



# King Faisal Specialist Hospital & Research Centre

Cancer Center of Excellence - Research Unit  
Riyadh

## **TUMOR REGISTRY** **ANNUAL REPORT** **2024**





مستشفى الملك فيصل التخصصي ومركز الأبحاث  
King Faisal Specialist Hospital & Research Centre

Cancer Center of Excellence  
Research Unit  
Riyadh

# TUMOR REGISTRY ANNUAL REPORT 2024

Classification: **Public** - عام

Annual Report Prepared by the Staff of the Tumor Registry  
Research Unit, Cancer Center of Excellence  
King Faisal Specialist Hospital and Research Centre  
P.O. Box 3354, Riyadh 11211  
Kingdom of Saudi Arabia  
464-7272 ext. 80778  
ORU@kfshrc.edu.sa

### **Tumor Registry Annual Report Committee Members**

Dr. Shouki Bazarbashi, Consultant, Medical Oncology  
Dr. Muhammad Anwar, Consultant, Medical Oncology  
Dr. Mohamed Rizwanullah, Consultant, Radiation Oncology  
Dr. Ayman Saad, Consultant, Hematology  
Dr. Marwan Shaheen, Consultant, Hematology

### **Tumor Registry Staff:**

Salma Aljared, Tumor Registrar  
Mohamed Alammari, Tumor Registrar  
Abdul Rasim Thurakkal, Tumor Registrar  
Rehab Alsawi, Tumor Registrar  
Faisal Alanazi, Tumor Registrar

**Doha Fatani, RPh, MPH, CCRP**

Supervisor - Research Unit

OCT 2025

Classification: Public - عام

**Table of Contents**

INTRODUCTION.....	6
<b>I. KING FAISAL SPECIALIST HOSPITAL &amp; RESEARCH CENTRE TUMOR REGISTRY .....</b>	<b>7</b>
<b>II. ACKNOWLEDGEMENTS .....</b>	<b>8</b>
<b>III. KFSH&amp;RC CANCER PATIENT POPULATION .....</b>	<b>9</b>
FIGURE 1: DISTRIBUTION OF CASES ACCESSIONED BY YEAR .....	9
TABLE 1: CASES SEEN AT KFSH&RC (MALE/FEMALE & PEDIATRICS/ADULTS) .....	10
FIGURE 2: DISTRIBUTION OF CASES BY NATIONALITY .....	10
FIGURE 3: DISTRIBUTION OF CASES BY REGION.....	11
FIGURE 4: DISTRIBUTION OF CASES BY REGION.....	12
<b>IV. TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&amp;RC.....</b>	<b>12</b>
FIGURE 5: DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES .....	13
FIGURE 6: DISTRIBUTION OF 5 MOST COMMON MALIGNANCIES .....	14
FIGURE 7: TEN MOST COMMON MALIGNANCIES.....	18
FIGURE 8: DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES.....	20
FIGURE 9 : DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES .....	21
TABLE 2: CASES SEEN AT KFSH&RC BY SITE AND YEAR .....	22
FIGURE 10: DISTRIBUTION OF ALL CASES BY AGE AT DIAGNOSIS.....	25
FIGURE 11: DISTRIBUTION OF PEDIATRIC CASES BY AGE AT DIAGNOSIS.....	26
TABLE 3: CASES SEEN AT KFSH&RC.....	27
BY SITE, SEX, CLASS OF CASE, AND SUMMARY STAGE (2024) .....	27
TABLE 4: ANALYTIC CASES SEEN AT KFSH&RC BY SITE AND AGE Group .....	28
TABLE 5: ANALYTIC MALE CASES SEEN AT KFSH&RC BY SITE AND AGE.....	29
TABLE 6: ANALYTIC FEMALE CASES SEEN AT KFSH&RC BY SITE AND AGE .....	30
<b>TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&amp;RC (cont'd).....</b>	<b>31</b>
TABLE 7: COMPARATIVE DATA - KFSH&RC vs USA .....	31
FIGURE 12: DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES.....	33
FIGURE 13: DISTRIBUTION OF MOST COMMON PEDIATRIC MALIGNANCIES.....	34
FIGURE 14: DISTRIBUTION OF MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY .....	34
TABLE 8: PRIMARY SITE (2024).....	35
TABLE 9: MULTIPLE PRIMARY SITE TABLE (2024) .....	49
<b>V. STAGE OF DISEASE AT DIAGNOSIS.....</b>	<b>51</b>
FIGURE 15: DISTRIBUTION OF CASES BY (SEER) STAGE AT DIAGNOSIS .....	52
TABLE 10: AJCC TNM GROUP STAGE OF ANALYTIC CASES OF MAJOR SITES .....	53
TABLE 11: ADDITIONAL CASES ADDED (2020-2023) .....	55

Classification: Public - عام

<b>VI. CANCER SURVIVAL AT KFSH&amp;RC .....</b>	<b>56</b>
TABLE 12: 5-YEAR OBSERVED SURVIVAL RATES** (%) .....	56
FIGURE 16: 5-YEAR OBSERVED SURVIVAL RATES (%).....	58
<b>VII. APPENDIX .....</b>	<b>72</b>
REQUESTS FOR TUMOR REGISTRY DATA (2024).....	72
<b>VIII. REFERENCES.....</b>	<b>733</b>
<b>IX. GLOSSARY OF TERMS .....</b>	<b>744</b>

Classification: Public - عام

## INTRODUCTION

We are pleased to present the 2024 Annual Tumor Registry Report for the King Faisal Specialist Hospital & Research Centre's Oncology Centre in Riyadh. The Cancer Registry maintains a complete database of information on all cancer cases diagnosed and/or treated at KFSH&RC. This database is an important patient care and quality assessment tool used by medical staff and administration for special studies, medical planning, resource allocation and utilization, education, and research for comparing the quality of care, monitoring patient care, and continuous quality improvement. This report highlights the statistical overview of newly diagnosed cancer cases by site, gender, and AJCC Staging for both analytic and non-analytic cases. During 2024, the Tumor Registry abstracted 5,129 new cancer cases. 4,737 cases were analytic, and 392 were non-analytic; the highest incidence of cancer among males by site was Colon& Rectum, Brain& CNS, Leukemia, and Prostate, and among females were carcinomas of the Breast, Uterus, Brain& CNS, and Thyroid. The Tumor Registry database includes over 125,003 cases and reports to the Saudi Cancer Registry (SCR).

Cancer Center of Excellence continues to provide comprehensive multidisciplinary care to our cancer patients. The Center provides the latest advances in radiation therapy, chemotherapy, hematopoietic stem cell transplantation, and palliative and rehabilitation care to our patients. We also continue to be a center of excellence in cancer clinical research. Involvement in clinical trials allows our physicians and researchers to actively advance new cancer treatments and provide the newest and most promising treatment options for our cancer patients. We have maintained our international cooperative group affiliations as a member of Southwest Oncology Group (SWOG), Radiation Therapy Oncology Group (RTOG/ NRG), and Canadian Blood & Marrow Transplantation Group (CBMTG). KFSH&RC has spearheaded the local and regional research consortiums as well, notably the Gulf Oncology Regional Group (GORG) and Eastern Mediterranean Blood and Marrow Transplantation (EMBT) Group.


The Oncology Center is committed to serving as the pinnacle of excellence in the entire region. As we look to the future of cancer care in the Kingdom of Saudi Arabia, the Oncology Centre will continue to deliver evidence-based care centered on state-of-the-art clinical and translational research.

We are extremely grateful to the dedicated staff of the Tumor Registry for their hard work and commitment throughout the year. Hats off to our physicians, patient caregivers, and support staff; their commitment and dedication are the foundation for our success.


This report can be accessed online via the Cancer Center of Excellence website at:

<https://www.kfshrc.edu.sa/en/home/hospitals/riyadh/oncologycentreadults/tumorregistryreports>

Comments and suggestions are welcome to improve our future reports and can be sent to [dfatani@kfshrc.edu.sa](mailto:dfatani@kfshrc.edu.sa)



**Doha Fatani, RPh, MPH, CCRP**  
Supervisor, Research Unit  
Cancer Center of Excellence



**Anders Mellgren, MD, PhD**  
Executive Director  
Cancer Center of Excellence

Classification: Public - عام

## **I. KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE TUMOR REGISTRY**

The King Faisal Specialist Hospital and Research Centre (KFSH&RC) opened in June 1975 to provide specialized medical treatment to the people of Saudi Arabia and promote disease prevention through research and education. It is a national and international tertiary care hospital for Oncology and the principal center for cancer therapy in Saudi Arabia.

The mission of the Tumor Registry, a hospital-wide data system, is to describe the burden of cancer in KFSH&RC by collecting complete and high-quality cancer data and compiling timely statistics so that data-driven, evidence-based cancer prevention and control programs can be implemented to reduce cancer morbidity and mortality.

The Registry was established to meet one of the requirements for an Approved Cancer Program of the American College of Surgeons (ACoS). The database now includes 125,003 malignant cases seen at KFSH&RC from June 1975 through December 31, 2024.

The Registry is primarily staffed with tumor registrars who support the database in case ascertainment, abstracting, follow-up, and statistical analyses. The basic source document is the patient's medical record, from which pertinent information is abstracted for use in the Registry. The electronic data system used was Cansur 3.0, designed by the ACoS, for cases from 1975 to 2007. Starting with 2008 cases, the software used is CNExT, developed by C/NET Solutions, part of the U.S. Public Health Institute.

The data maintained in the Tumor Registry provides the statistics for the publication of the KFSH&RC Annual Report, which summarizes the hospital's cancer experience. The data also supports various reports at the request of physicians, researchers, and ancillary personnel. These reports support patient management and outcomes, basic and clinical research investigations, educational publications and presentations, and resource utilization. In 2024, the Tumor Registry supported a myriad of data requests. It also identified and reported to the Saudi Cancer Registry 5,129 new cases seen in 2024.

Classification: Public - عام

## II. ACKNOWLEDGEMENTS

The cancer program is a combined effort of the extraordinary team of professionals at the King Faisal Specialist Hospital and Research Centre. It is not possible to enumerate all those involved in providing hope and healing to cancer patients and their families. The Tumor Registry staff greatly appreciates the tireless efforts of caring professionals from all disciplines for their dedication, commitment, and collaboration to ensure the highest standards in community outreach, clinical trials, staff education, patient care improvement, outcome analysis, and tumor registry quality.

Our team's clinical expertise and proficiency, coupled with an incredible dedication to patient care and service excellence, allow the Oncology Centre to achieve remarkable outcomes and consistently exceed the needs and expectations of patients and their families.

The information in this report includes cancer incidence, site, and extent of disease at diagnosis, treatment, cancer trends, and outcomes to better understanding of the changing patterns of cancer.

The following departments have assisted throughout the year, and without their support, this report would not have been possible. The Tumor Registry staff takes pride in acknowledging these departments:


- Department of Pathology and Laboratory Medicine
- Medical Records Services
- Patients Acceptance Affairs
- Information Technology Affairs
- Central Data Unit, Department of Pediatric Hematology/Oncology
- Radiation Oncology Department
- Radiology Department
- Saudi Cancer Registry
- Home Health Care
- Cancer Center of Excellence

Classification: Public - عام

### III. KFSH&RC CANCER PATIENT POPULATION

A total of 5,129 cases were accessioned in 2024, with 2,197 males and 2,932 females or a male/female ratio of 0.7:1.

**FIGURE 1**  
**DISTRIBUTION OF CASES ACCESSIONED BY YEAR**  
 1975-2024 (TOTAL CASES = 125,003)



From the hospital's opening (mid-1975) until December 2024, 125,003 cancer cases were registered (59,910 males and 65,093 females), with a male/female ratio of 0.9:1.

There were 13,288 (10.6%) pediatric cases (0 to 13 years of age) and 111,715 (89.4%) adults (14 years old and above). In 2024, the proportions were 6.1% (313) for pediatrics and 93.9% (4,816) for adults.

Classification: Public - عام

**TABLE 1**  
**CASES SEEN AT KFSH&RC (MALE/FEMALE & PEDIATRICS/ADULTS)**  
 BY 5-YEAR PERIOD (1975-2024)



	1975-1976*	1977-1981	1982-1986	1987-1991	1992-1996	1997-2001	2002 - 2006	2007-2011	2012-2016	2017-2021	2022-2024**	TOTAL
<b>MALE</b>	293	3,111	4,417	5,414	5,814	6,680	6,698	6,081	6,808	8,144	6,450	59,910
<b>FEMALE</b>	151	2,091	3,613	4,842	5,697	7,182	7,490	7,328	8,245	10,105	8,349	65,093
<b>TOTAL</b>	<b>444</b>	<b>5,202</b>	<b>8,030</b>	<b>10,256</b>	<b>11,511</b>	<b>13,862</b>	<b>14,188</b>	<b>13,409</b>	<b>15,053</b>	<b>18,249</b>	<b>14,799</b>	<b>125,003</b>
<b>M/F RATIO</b>	<b>1.9:1</b>	<b>1.4:1</b>	<b>1.2:1</b>	<b>1.1:1</b>	<b>1.0:1</b>	<b>0.9:1</b>	<b>0.8:1</b>	<b>0.8:1</b>	<b>0.8:1</b>	<b>0.8:1</b>	<b>0.8:1</b>	<b>0.9:1</b>
<b>PEDIATRICS***</b>	57	601	1,039	1,312	1,397	1,863	1,835	1,564	1,341	1,343	936	13,288
<b>(%)</b>	12.84%	11.55%	12.94%	12.79%	12.14%	13.44%	12.93%	11.66%	8.91%	7.36%	6.32%	12.27%
<b>ADULTS</b>	387	4,601	6,991	8,944	10,114	11,999	12,353	11,845	13,712	16,906	13,863	111,715
<b>(%)</b>	87.16%	88.45%	87.06%	87.21%	87.86%	86.56%	87.07%	88.34%	91.09%	92.64%	93.68%	89.37%
<b>TOTAL</b>	<b>444</b>	<b>5,202</b>	<b>8,030</b>	<b>10,256</b>	<b>11,511</b>	<b>13,862</b>	<b>14,188</b>	<b>13,409</b>	<b>15,053</b>	<b>18,249</b>	<b>14,799</b>	<b>125,003</b>

\* First two years of KFSH&amp;RC partial operation.

\*\* The last period from 2022 to 2024 represents a three-year interval.

\*\*\* Pediatrics = 0 to 13 years of age; Adults = 14 years and above.

**FIGURE 2**  
**DISTRIBUTION OF CASES BY NATIONALITY**  
 BY 5-YEAR PERIOD (2020-2024) TOTAL CASES =22,549



\*GC: Gulf countries (Bahrain, Kuwait, Qatar, Oman and United Arab Emirates).


Classification: Public - عام

Geographically, the referral pattern in 2024 was mainly from the Riyadh region with 45.7% of all cases, followed by the Eastern Province with 9.7% then the Asir region with 7.7% respectively. During the 49 years in review, 36.3% were referred from Riyadh, 12.3% from the Eastern Province and 8.9% from Mekkah.


These percentages reflect the KFSH&RC's experience rather than being adjusted to reflect the population of those regions.

**FIGURE 3**  
**DISTRIBUTION OF CASES BY REGION**  
(Based on Given Address at Time of Diagnosis)

**1975-2024 (TOTAL CASES = 125,003)**



**2024 (TOTAL CASES = 5,129)**




BH-ALBAHA, NB-NORTHERN BORDERS  
JZ-JAZAN, QS- QASSIM

Classification: Public - عام

Classification: Public - عام

**FIGURE 4**  
**DISTRIBUTION OF CASES BY REGION**  
 (1975-2024)



RY: Riyadh, ER: Eastern Region, MK: Makkah, AS: Asir, QS: Qassim, MD: Madinah, JF: Jouf, JZ: Jazan, HL: Hail, TB: Tabouk, NJ: Najran, OT: Other, NB: Northern Borders, UNK: Unknown, BH: Baha

Classification: Public - عام


#### IV. TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&RC

Acceptance of cases to KFSH&RC is based on eligibility criteria, considering the nature of the disease and availability of services.

Breast cancer led the list of total cancer cases seen from 2020 to 2024 with (16.6%), followed by Brain & CNS (8.7%), Colon & Rectum (8.1%), Thyroid (7.1%), and Leukemia (6.6%)

**FIGURE 5**  
**DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES**

5-YEAR PERIOD (2020-2024) TOTAL CASES = 22,549





\*Other Endocrine: include (Parathyroid, Adrenal) excluding Thyroid.



\* Brain, CNS: includes Benign Tumors.

Classification: Public - عام

**FIGURE 6**  
**DISTRIBUTION OF 5 MOST COMMON MALIGNANCIES**  
**BY AGE AT DIAGNOSIS AND SEER SUMMARY STAGE**  
**5-YEAR PERIOD (2020 – 2024)**





Classification: Public - عام





Classification: Public - عام

### COLON & RECTUM CANCER CASES




Classification: Public - عام

### THYROID CANCER CASES



### LEUKEMIA CASES



Reference; SEER Summary stage 2018  
Leukemia: include all sub-types (ALL, AML, CLL, CML)

Classification: Public - عام

Classification: Public - عام

**FIGURE 7**  
**TEN MOST COMMON MALIGNANCIES**  
 BY AGE GROUP AT DIAGNOSIS  
 5-YEAR PERIOD (2020-2024)

BREAST	
0-13 (CHILD)	0
14-19 (TEEN)	4
20-29	97
30-39	624
40-49	1082
50-59	985
60-69	689
70-79	211
+80	49

BRAIN,CNS	
0-13 (CHILD)	287
14-19 (TEEN)	83
20-29	182
30-39	323
40-49	374
50-59	358
60-69	234
70-79	109
+80	23

COLON & RECTUM	
0-13 (CHILD)	6
14-19 (TEEN)	5
20-29	42
30-39	162
40-49	376
50-59	508
60-69	423
70-79	216
+80	85

THYROID	
0-13 (CHILD)	16
14-19 (TEEN)	54
20-29	271
30-39	404
40-49	365
50-59	270
60-69	159
70-79	48
+80	11

LEUKEMIA	
0-13 (CHILD)	423
14-19 (TEEN)	142
20-29	180
30-39	181
40-49	177
50-59	171
60-69	145
70-79	46
+80	23

NON-HODGKIN LYMPHOMA	
0-13 (CHILD)	128
14-19 (TEEN)	73
20-29	158
30-39	203
40-49	192
50-59	249
60-69	205
70-79	76
+80	37

Classification: Public - عام

UTERUS	
0-13 (CHILD)	0
14-19 (TEEN)	0
20-29	18
30-39	112
40-49	171
50-59	292
60-69	429
70-79	162
+80	51

LIVER	
0-13 (CHILD)	24
14-19 (TEEN)	8
20-29	14
30-39	17
40-49	47
50-59	193
60-69	301
70-79	152
+80	58


HODGKIN LYMPHOMA	
0-13 (CHILD)	108
14-19 (TEEN)	113
20-29	186
30-39	136
40-49	58
50-59	36
60-69	26
70-79	4
+80	0

KIDNEY	
0-13 (CHILD)	75
14-19 (TEEN)	5
20-29	19
30-39	81
40-49	126
50-59	138
60-69	126
70-79	62
+80	8

Classification: Public - عام

Cancer among pediatrics (under the age of 14) accounted for 6.7% of all cases from 2020 to 2024. The five most common pediatric malignancies were Leukemia (28.03%), Brain, CNS (19.02%), Non-Hodgkin lymphoma (8.5%), Hodgkin Lymphoma (7.2%), and Bone (6.9%).

**FIGURE 8**  
**DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES**  
 BY 5-YEAR PERIOD (2020 – 2024) TOTAL CASES= 1,509




\*Leukemia: include all sub-types (ALL, AML, CLL, CML).

\*\*Brain, CNS: includes Benign Tumors.

Classification: Public - عام

**FIGURE 9**  
**DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES**  
 BY Sub-Types  
 5-YEAR PERIOD (2020-2024) TOTAL CASES = 1,509



\*Leukemia: include all sub-types (ALL, AML, CLL, CML).

**TABLE 2**  
**CASES SEEN AT KFSH&RC BY SITE AND YEAR**  
 (1975-2024)


Site Group	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
Oral Cavity	1	8	21	59	43	53	43	59	74	52	80	56	76	95	83	75	86
Tonsil	0	1	2	4	7	3	4	3	6	2	5	4	3	3	2	5	0
Nasopharynx	3	16	49	51	56	51	60	66	87	70	64	70	101	98	85	88	80
Esophagus	1	15	51	62	67	67	57	62	77	78	56	69	76	66	68	72	66
Stomach	2	15	32	35	50	37	49	51	64	60	49	64	61	48	52	53	36
Small intestine	0	0	4	0	2	2	2	1	1	5	3	5	2	1	6	4	1
Colon & Rectum	1	13	21	20	28	37	45	37	36	52	39	45	72	79	58	58	76
Anus,anal canal,anorectum	0	0	1	4	3	1	7	4	7	9	7	7	4	4	5	8	6
Liver	7	15	33	44	49	33	41	54	53	64	57	84	78	71	68	56	69
Gallbladder	0	2	3	4	2	2	4	6	4	4	6	7	14	9	5	9	9
Bile ducts	1	1	0	2	2	4	1	2	3	4	4	6	6	6	2	4	2
Pancreas	1	5	7	11	15	14	20	22	14	20	16	28	20	17	29	13	14
Peritoneum,Retroperitoneum	0	0	2	1	2	1	0	0	2	1	0	1	1	1	1	1	0
Other digestive	0	0	0	2	2	5	4	1	1	0	3	1	4	3	6	2	1
Nasal cavity,sinus,ear	1	3	9	7	5	7	9	10	10	5	7	5	16	14	8	13	12
Larynx	1	5	12	12	12	14	20	13	23	22	25	16	23	33	21	26	35
Lung/bronchus	3	11	23	34	45	40	56	63	74	74	87	84	85	106	90	74	85
Pleura	0	0	1	0	0	0	0	0	1	1	0	1	0	1	2	2	0
Other respir & thoracic	0	0	0	1	1	1	3	1	1	0	4	0	6	2	2	3	9
Leukemia	8	32	48	94	98	94	136	134	132	144	140	197	224	191	187	168	197
Myeloma	1	5	6	11	9	11	8	13	13	12	19	13	29	22	33	15	28
Bone	1	7	15	27	25	21	28	45	36	47	25	39	48	52	49	46	47
Soft tissue	4	19	29	38	39	38	43	46	55	66	65	76	102	92	118	112	105
Skin	2	17	31	40	50	42	55	58	62	64	69	69	54	55	59	47	58
Kaposi sarcoma	0	1	1	0	6	4	2	2	5	4	5	9	5	9	5	4	5
Breast	3	24	53	46	57	65	101	111	111	153	131	127	174	194	137	168	169
Uterus	1	11	20	23	31	22	34	33	44	47	51	65	68	71	54	62	48
Ovary	2	7	11	10	17	21	21	36	31	28	24	36	43	50	54	51	41
Vagina	0	0	5	2	0	1	2	0	2	2	3	1	2	1	2	3	3
Vulva	0	0	0	1	1	0	2	1	3	2	5	5	1	2	1	4	5
Other female genital	0	1	5	4	9	8	7	8	24	9	7	17	24	17	15	9	16
Prostate	0	7	5	4	5	10	11	18	28	19	19	17	22	27	27	24	16
Testis	0	3	9	8	10	11	15	11	7	12	14	14	17	17	9	14	14
Penis	0	1	1	0	1	0	2	2	3	4	0	0	0	2	2	5	2
Other male genital	0	0	0	0	2	0	1	0	1	0	3	0	3	0	2	0	0
Bladder	4	7	12	24	29	40	37	23	41	36	46	51	79	74	73	60	45
Kidney and renal pelvis	0	9	18	18	18	15	18	30	23	20	24	41	31	58	32	36	33
Ureter	0	0	0	0	0	0	0	0	0	1	1	0	3	1	1	0	1
Other urinary	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	1
Eye	0	6	11	19	12	24	29	34	25	17	30	25	35	45	26	30	9
Brain,CNS	4	29	35	57	38	41	56	107	71	73	68	102	135	136	137	116	120
Thyroid	2	8	17	29	37	47	59	54	68	71	64	88	121	117	113	95	114
Other endocrine	2	11	14	11	20	27	30	31	38	47	35	37	41	53	33	40	46
Hodgkin's disease	13	19	40	41	36	42	47	42	54	50	49	45	65	57	76	56	57
Non-hodgkin's lymphoma	4	23	73	75	103	112	128	116	172	139	124	142	157	153	165	154	123
Unknown or ill-defined	3	11	23	24	20	27	34	30	33	26	25	25	38	33	43	39	40
<b>TOTAL</b>	<b>76</b>	<b>368</b>	<b>753</b>	<b>959</b>	<b>1064</b>	<b>1095</b>	<b>1331</b>	<b>1440</b>	<b>1620</b>	<b>1617</b>	<b>1558</b>	<b>1795</b>	<b>2169</b>	<b>2186</b>	<b>2047</b>	<b>1924</b>	<b>1930</b>

Site Group	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Oral Cavity	96	72	74	94	81	87	69	92	100	69	68	99	78	101	82	103	90
Tonsil	2	3	2	4	0	5	2	1	2	4	5	8	0	5	1	5	4
Nasopharynx	82	85	80	85	113	109	124	119	98	143	87	111	117	97	91	84	89
Esophagus	69	47	50	50	52	52	62	34	52	37	42	43	37	41	36	30	31
Stomach	49	42	68	61	59	47	42	56	54	40	50	60	68	57	59	48	52
Small intestine	5	4	4	6	6	4	7	7	9	5	3	5	9	6	4	5	6
Colon & Rectum	83	72	88	88	91	96	120	145	154	154	205	206	191	197	191	182	166
Anus,anal canal,anorectum	7	12	10	5	6	6	7	4	7	7	8	14	5	5	3	5	5
Liver	83	82	105	102	105	96	84	90	85	92	73	70	60	37	69	50	73
Gallbladder	13	19	21	9	11	11	12	15	13	11	12	15	14	8	8	11	10
Bile ducts	7	2	7	3	9	7	10	9	8	9	10	7	4	8	6	11	7
Pancreas	27	21	23	26	21	24	34	18	38	26	31	30	34	27	42	26	33
Peritoneum,Retroperitoneum	2	1	0	2	0	0	1	2	2	1	1	1	4	4	3	3	3
Other digestive	2	4	0	3	0	0	0	0	0	2	0	3	4	2	1	1	4
Nasal cavity,sinus,ear	9	10	11	10	9	4	10	14	11	9	11	10	9	13	13	12	9
Larynx	27	31	35	37	36	31	30	36	32	33	26	47	41	36	26	32	31
Lung/bronchus	79	85	89	87	84	88	106	108	91	80	91	86	94	84	64	60	63
Pleura	3	4	3	1	2	1	1	2	3	8	1	4	3	3	1	3	2
Other respir & thoracic	7	7	8	4	4	8	8	9	2	1	5	2	4	3	4	1	6
Leukemia	175	204	180	225	181	242	257	289	272	252	270	268	230	214	237	215	253
Myeloma	26	25	40	30	21	14	23	16	28	20	19	20	23	23	22	31	18
Bone	65	59	68	65	63	74	79	72	80	94	83	66	74	72	72	56	86
Soft tissue	67	62	83	96	62	80	86	101	84	79	70	83	89	75	58	85	63
Skin	64	61	68	51	66	57	40	65	57	67	44	57	57	61	74	35	49
Kaposi sarcoma	14	2	3	6	11	6	8	8	4	7	9	9	6	8	9	7	7
Breast	188	251	241	232	282	294	337	343	383	362	378	411	433	379	326	351	358
Uterus	79	70	78	72	68	73	92	90	76	103	100	114	109	94	97	107	108
Ovary	46	60	57	58	58	66	66	61	68	63	55	65	63	54	60	55	75
Vagina	2	0	5	5	2	2	1	2	1	0	1	1	2	1	0	0	0
Vulva	1	4	5	5	2	1	0	1	2	3	2	2	3	2	0	2	4
Other female genital	15	13	20	7	11	9	7	6	5	5	10	14	13	12	16	8	6
Prostate	41	27	45	37	49	43	44	63	47	49	49	59	59	75	46	40	60
Testis	21	25	21	14	15	17	16	19	21	18	28	19	21	17	11	17	28
Penis	0	1	3	0	1	3	0	0	2	0	1	1	0	2	0	0	0
Other male genital	0	1	1	0	0	0	1	0	0	1	2	1	2	1	2	0	0
Bladder	66	88	72	60	56	65	85	91	80	82	71	93	102	89	67	69	71
Kidney and renal pelvis	52	52	65	48	47	50	59	71	57	72	65	55	70	64	67	70	86
Ureter	1	1	1	1	1	0	3	1	2	3	2	2	1	2	0	1	0
Other urinary	1	0	0	0	0	0	0	2	1	0	0	0	1	2	0	0	0
Eye	15	39	27	15	22	31	17	24	26	17	16	21	18	15	20	11	19
Brain,CNS	153	140	163	177	178	180	216	212	235	242	219	194	204	164	154	119	143
Thyroid	143	136	159	134	162	161	192	211	186	189	169	215	214	216	206	229	254
Other endocrine	46	30	24	20	31	37	27	29	33	29	32	56	46	45	34	27	55
Hodgkin's disease	75	73	78	88	76	76	98	116	131	121	121	132	144	130	101	118	118
Non-hodgkin's lymphoma	151	154	160	158	157	193	208	207	204	175	186	206	218	181	167	178	172
Unknown or ill-defined	52	42	62	36	42	35	50	50	46	49	53	48	49	33	29	19	25
<b>TOTAL</b>	<b>2211</b>	<b>2223</b>	<b>2407</b>	<b>2317</b>	<b>2353</b>	<b>2485</b>	<b>2741</b>	<b>2911</b>	<b>2892</b>	<b>2833</b>	<b>2784</b>	<b>3033</b>	<b>3027</b>	<b>2765</b>	<b>2579</b>	<b>2522</b>	<b>2742</b>


Site Group	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TOTAL
Oral Cavity	91	62	87	74	81	87	90	96	77	90	77	85	66	86	89	83	3740
Tonsil	1	0	4	1	3	2	2	1	2	0	1	0	1	3	1	2	131
Nasopharynx	67	85	86	70	81	69	68	77	85	80	75	67	105	97	81	104	4106
Esophagus	31	29	31	30	21	30	25	26	30	33	32	29	26	28	29	46	2251
Stomach	64	65	59	61	67	76	57	43	40	40	62	42	78	68	55	90	2637
Small intestine	7	5	9	10	11	21	7	9	11	6	8	14	15	18	20	21	326
Colon & Rectum	188	169	197	202	213	235	267	249	292	207	263	224	369	398	397	435	7451
Anus,anal canal,anorectum	1	4	2	3	5	7	4	10	6	2	3	5	9	14	4	7	279
Liver	89	97	112	107	105	95	104	113	111	133	127	120	186	182	172	154	4239
Gallbladder	6	9	11	5	11	23	17	12	21	22	28	28	25	25	19	26	591
Bile ducts	12	13	8	10	9	12	17	16	7	9	19	28	35	26	34	27	456
Pancreas	40	38	31	46	61	62	48	50	63	54	81	68	92	116	131	125	1853
Peritoneum,Retroperitoneum	2	3	2	6	9	5	5	16	13	11	10	16	11	9	14	8	184
Other digestive	1	2	0	0	1	0	3	2	9	6	7	1	7	10	8	17	135
Nasal cavity,sinus,ear	8	5	4	7	4	4	11	10	12	14	5	12	13	7	10	12	453
Larynx	26	10	17	19	21	18	24	20	18	27	18	19	34	32	25	11	1219
Lung/bronchus	61	63	73	72	82	92	65	79	82	81	109	71	118	131	132	157	3941
Pleura	4	1	0	3	3	0	4	1	2	1	2	2	2	2	0	2	83
Other respir & thoracic	7	9	7	5	5	2	3	6	2	0	3	3	5	7	2	3	186
Leukemia	242	267	231	294	269	263	253	293	293	280	275	252	289	326	323	298	10636
Myeloma	39	36	28	16	32	26	25	30	23	30	27	35	48	45	50	47	1184
Bone	66	72	65	58	50	72	39	54	74	67	70	72	101	73	71	78	2868
Soft tissue	62	74	69	74	73	64	68	57	48	73	95	69	96	134	156	163	3745
Skin	47	46	48	43	53	50	56	56	58	39	58	29	38	38	48	44	2556
Kaposi sarcoma	7	10	5	3	5	13	10	4	8	3	6	5	11	7	6	6	300
Breast	339	377	414	377	433	490	402	422	508	501	595	505	729	840	823	844	15972
Uterus	120	89	107	115	98	144	126	118	139	149	165	191	203	239	259	343	4820
Ovary	64	79	61	65	66	71	55	57	47	64	73	55	91	90	79	93	2623
Vagina	2	0	2	1	0	1	4	2	1	2	1	0	0	1	2	4	77
Vulva	4	2	5	4	2	2	1	2	7	1	1	1	7	2	5	7	125
Other female genital	10	4	4	2	6	4	5	2	0	3	1	4	3	12	7	5	429
Prostate	45	48	37	38	49	70	68	62	69	89	90	72	129	157	124	151	2390
Testis	28	30	23	14	28	33	39	25	25	28	43	41	47	51	53	66	1087
Penis	1	0	0	2	0	0	0	1	0	3	1	1	1	1	1	2	53
Other male genital	0	0	1	1	0	0	2	3	0	1	0	1	0	1	1	0	35
Bladder	70	87	67	63	80	75	75	92	81	85	103	65	104	107	106	116	3364
Kidney and renal pelvis	86	85	87	84	78	97	93	102	102	89	133	74	125	127	141	173	3150
Ureter	2	2	2	0	0	0	1	1	0	0	3	0	0	6	1	2	50
Other urinary	0	0	0	3	1	1	2	1	1	1	1	3	2	3	3	3	36
Eye	17	24	32	27	22	23	21	21	27	21	17	24	25	17	21	20	1089
Brain,CNS	134	181	177	192	172	175	205	203	207	218	344	303	359	418	393	500	8599
Thyroid	226	214	245	248	247	287	293	300	315	300	307	220	329	362	375	312	8860
Other endocrine	41	42	35	47	41	49	51	31	57	85	88	54	74	100	92	95	2099
Hodgkin's disease	122	104	96	117	108	146	114	121	141	129	146	111	133	151	136	136	4596
Non-hodgkin's lymphoma	149	163	141	155	163	157	190	172	206	200	259	195	332	270	257	267	8314
Unknown or ill-defined	31	33	25	25	41	30	27	47	44	15	11	29	32	44	33	24	1685
<b>TOTAL</b>	<b>2660</b>	<b>2738</b>	<b>2747</b>	<b>2799</b>	<b>2910</b>	<b>3183</b>	<b>3046</b>	<b>3115</b>	<b>3364</b>	<b>3292</b>	<b>3843</b>	<b>3245</b>	<b>4505</b>	<b>4881</b>	<b>4789</b>	<b>5129</b>	<b>125003</b>

The largest number of cases in 2024 was noted in the 6th and 7th decades of life in males and in the 7th in females. The mean age was 46, the median was 55, and the mode was 58. Pediatric malignancies were most common among children at one year of age and at two years of age.

**FIGURE 10**  
**DISTRIBUTION OF ALL CASES BY AGE AT DIAGNOSIS**  
2024 (TOTAL CASES = 5,129)



**FIGURE 11**  
**DISTRIBUTION OF PEDIATRIC CASES BY AGE AT DIAGNOSIS**  
 2024 (TOTAL CASES = 313)



Of the 5,129 cases in 2024, 4,737 (92.3%) were analytic (defined as cases that were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC). The remaining 392 cases (7.6%) were non-analytic (defined as cases diagnosed elsewhere and received their entire first course of treatment elsewhere). Pediatric cases totaled 313, with 179 males and 134 females.

See Table 3 for the distribution of cases by site, sex, class of case, and stage at diagnosis.

TABLE 3  
CASES SEEN AT KFSH&RC  
BY SITE, SEX, CLASS OF CASE, AND SUMMARY STAGE  
(2024)

- **\*Analytic case** refers to a cancer case who was diagnosed and/or received all or part of their first course of treatment at the facility reporting the data.
- **\*\*Non-analytic** Case seen at our facility for subsequent treatment of a recurrence, second opinions, or follow-up after receiving initial care elsewhere.

Site Group	Total Cases	Class		Sex		STAGE					
		Analytic*	NonAn**	M	F	In situ	Localized	Regional	Distant	Benign Brain, CNS	Unstageable
ORAL CAVITY	83	83	0	50	33	0	41	38	3	0	1
TONSIL	2	2	0	2	0	0	0	2	0	0	0
NASOPHARYNX	104	100	4	74	30	0	9	78	16	0	1
ESOPHAGUS	46	45	1	24	22	1	12	21	10	0	2
STOMACH	90	85	5	46	44	0	25	21	42	0	2
SMALL INTESTINE	21	18	3	10	11	0	6	5	9	0	1
COLON & RECTUM	435	382	53	223	212	3	95	202	131	0	4
ANUS,ANAL CANAL,,ANORECTUM	7	6	1	5	2	0	1	4	2	0	0
LIVER	154	146	8	102	52	0	101	15	38	0	0
GALLBLADDER	26	25	1	6	20	0	7	7	12	0	0
BILE DUCTS	27	25	2	21	6	0	4	10	13	0	0
PANCREAS	125	109	16	84	41	0	21	36	67	0	1
PERITONEUM, RETROPERITONEUM	8	8	0	5	3	0	1	2	5	0	0
OTHER DIGESTIVE	17	16	1	5	12	0	0	0	14	0	3
NASAL CAVITY,SINUS,EAR	12	12	0	8	4	0	8	4	0	0	0
LARYNX	11	10	1	11	0	0	8	2	1	0	0
LUNG & BRONCHUS	157	149	8	111	46	0	31	29	97	0	0
PLEURA	2	2	0	2	0	0	0	2	0	0	0
OTHER RESPIR & THORACIC	3	3	0	2	1	0	1	1	1	0	0
LEUKEMIA	298	277	21	167	131	0	8	0	286	0	4
MYELOMA	47	43	4	26	21	0	1	0	45	0	1
BONE	78	70	8	47	31	0	48	6	24	0	0
SOFT TISSUE	163	150	13	81	82	0	91	18	54	0	0
SKIN	44	42	2	30	14	4	27	4	8	0	1
KAPOSIS SARCOMA	6	6	0	4	2	0	3	1	0	0	2
BREAST	844	767	77	12	832	76	246	356	161	0	5
UTERUS	343	316	27	0	343	15	194	59	74	0	1
OVARY	93	80	13	0	93	1	34	22	35	0	1
VAGINA	4	4	0	0	4	0	1	1	2	0	0
VULVA	7	7	0	0	7	0	5	2	0	0	0
OTHER FEMALE GENITAL	5	5	0	0	5	0	0	0	5	0	0
PROSTATE	151	127	24	151	0	0	67	25	53	0	6
TESTIS	66	58	8	66	0	0	51	9	6	0	0
PENIS	2	2	0	2	0	0	1	1	0	0	0
BLADDER	116	105	11	101	15	37	51	13	15	0	0
KIDNEY AND RENAL PELVIS	173	167	6	115	58	1	113	25	32	0	2
URETER	2	2	0	1	1	1	1	0	0	0	0
OTHER URINARY	3	3	0	3	0	0	0	1	2	0	0
EYE	20	19	1	11	9	0	14	4	2	0	0
BRAIN, CNS	500	475	25	209	291	0	172	50	7	271	0
THYROID	312	298	14	77	235	2	178	115	16	0	1
OTHER ENDOCRINE	95	89	6	53	42	0	18	6	15	55	1
HODGKIN'S DISEASE	136	129	7	89	47	0	32	35	69	0	0
NON-HODGKIN'S LYMPHOMA	267	246	21	151	116	0	65	29	171	0	2
UNKNOWN OR ILL-DEFINED	24	24	0	10	14	0	1	3	9	0	11
TOTAL	5129	4737	392	2197	2932	141	1793	1264	1552	326	53

TABLE 4  
ANALYTIC CASES SEEN AT KFSH&RC BY SITE AND AGE GROUP  
(2024)

Site Group	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	TOTAL
Oral cavity	0	0	1	1	1	2	6	2	7	5	10	8	12	9	8	5	5	1	83
Tonsil	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2
Nasopharynx	0	0	1	1	4	0	5	11	10	11	14	17	10	8	6	2	0	0	100
Esophagus	0	0	0	0	0	0	2	3	3	4	7	3	6	6	3	2	4	2	45
Stomach	0	0	0	0	3	2	7	6	14	5	7	8	16	7	5	4	1	0	85
Small intestine	0	0	0	0	0	1	2	2	0	3	0	2	3	1	2	0	0	2	18
Colon & Rectum	0	0	0	1	3	7	13	15	35	51	44	65	52	34	27	19	11	5	382
Anus,anal canal,anorectum	0	0	0	0	0	0	0	0	0	2	1	1	2	0	0	0	0	0	6
Liver	0	0	0	2	2	2	1	0	2	6	10	21	33	31	11	13	4	8	146
Gallbladder	0	0	0	0	0	0	1	1	2	0	3	3	3	7	1	3	1	0	25
Bile ducts	0	0	0	0	0	0	0	0	0	4	3	7	2	4	2	2	1	0	25
Pancreas	0	0	0	0	1	1	2	3	9	11	7	19	15	13	17	3	5	3	109
Retroperitoneum, Peritoneum	2	0	0	0	0	1	0	0	0	0	0	0	2	1	1	1	0	0	8
Other digestive	0	0	0	1	0	1	0	0	2	0	2	0	5	1	0	2	1	1	16
Nasal cavity,sinus,ear	0	0	0	1	1	0	1	1	1	0	1	0	2	1	2	0	0	1	12
Larynx	0	0	0	0	0	0	1	0	1	0	0	0	2	3	1	1	1	0	10
Lung & Bronchus	2	0	0	0	0	2	1	7	9	14	15	17	17	25	11	16	9	4	149
Pleura	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2
Other respir & thoracic	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3
Leukemia	43	24	19	27	20	13	16	18	19	11	11	15	19	12	6	2	2	0	277
Myeloma	0	0	0	0	0	0	0	2	6	5	4	10	4	4	5	2	1	0	43
Bone	2	7	17	10	4	10	3	4	1	4	1	3	1	1	0	2	0	0	70
Soft tissue	14	7	4	7	10	8	3	14	10	17	7	13	13	10	7	4	2	0	150
Skin	0	0	0	2	1	3	1	1	3	4	4	2	3	2	6	2	4	4	42
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	3	0	0	2	0	0	6
Breast	0	0	0	1	3	15	33	76	108	131	91	107	100	52	28	12	6	4	767
Uterus	0	0	0	0	0	3	7	23	27	18	24	38	64	57	29	8	8	10	316
Ovary	1	0	0	2	1	4	5	7	4	11	7	10	5	12	6	3	0	2	80
Vagina	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	1	4
Vulva	0	0	0	0	1	1	0	0	1	0	0	1	1	0	1	1	0	0	7
Other female genital	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	0	1	0	5
Prostate	0	0	0	0	0	0	0	0	2	1	4	19	24	30	22	10	8	7	127
Testis	1	0	0	0	8	10	16	13	5	1	3	0	1	0	0	0	0	0	58
Penis	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	2
Bladder	0	0	2	0	0	2	2	4	5	7	5	18	7	18	9	14	7	5	105
Kidney and renal pelvis	11	4	2	0	1	6	8	11	15	16	13	20	29	12	11	6	2	0	167
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	2
Other urinary	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	3
Eye	18	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	19
Brain, CNS	26	19	17	26	19	27	38	38	45	47	52	38	28	29	14	8	4	0	475
Thyroid	0	0	3	12	12	33	45	42	35	29	28	23	17	12	2	3	1	1	298
Other endocrine	9	1	2	1	3	3	11	12	9	5	10	6	9	4	4	0	0	0	89
Hodgkin's disease	0	5	13	22	16	9	12	22	10	3	2	4	7	3	1	0	0	0	129
Non-hodgkin's lymphoma	3	6	3	8	9	13	10	26	27	10	24	30	29	19	12	8	5	4	246
Unknown or ill-defined	7	2	0	0	0	2	1	1	1	0	1	4	2	0	0	1	2	0	24
TOTAL	142	75	84	125	124	182	254	366	429	436	416	536	552	431	261	161	98	65	4737

TABLE 5  
ANALYTIC MALE CASES SEEN AT KFSH&RC BY SITE AND AGE  
(2024)

Site Group	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	TOTAL
Oral cavity	0	0	1	1	1	1	4	1	4	3	4	5	8	5	4	3	4	1	50
Tonsil	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2
Nasopharynx	0	0	1	1	2	0	2	9	9	7	11	8	7	8	5	1	0	0	71
Esophagus	0	0	0	0	0	0	0	1	1	2	3	1	4	5	2	1	3	0	23
Stomach	0	0	0	0	1	0	3	3	10	2	2	5	7	5	4	1	0	0	43
Small intestine	0	0	0	0	0	1	2	1	0	1	0	2	1	0	1	0	0	1	10
Colon & Rectum	0	0	0	0	0	1	3	7	18	30	20	30	31	23	14	10	5	1	193
Anus,anal canal,anorectum	0	0	0	0	0	0	0	0	0	2	1	0	1	0	0	0	0	0	4
Liver	0	0	0	1	1	1	1	0	2	5	7	11	25	22	8	5	4	2	95
Gallbladder	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	1	0	6
Bile ducts	0	0	0	0	0	0	0	0	0	4	2	5	1	4	1	2	1	0	20
Pancreas	0	0	0	0	1	1	0	1	8	9	4	10	11	11	10	1	4	2	73
Peritoneum, Retroperitoneum	2	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0	0	0	5
Other digestive	0	0	0	0	0	1	0	0	1	0	0	0	2	0	0	0	0	1	5
Nasal cavity,sinus,ear	0	0	0	0	0	0	1	1	0	0	1	0	2	0	2	0	0	1	8
Larynx	0	0	0	0	0	0	1	0	1	0	0	0	2	3	1	1	1	0	10
Lung	1	0	0	0	0	2	1	2	3	9	12	13	10	19	10	12	9	3	106
Pleura	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2
Other respir & thoracic	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	2
Myeloma	0	0	0	0	0	0	0	1	4	3	1	3	3	2	4	2	1	0	24
Leukemia	22	16	12	18	13	6	10	7	8	6	6	8	10	4	2	1	2	0	151
Bone	1	3	9	6	4	9	1	2	0	3	0	2	0	0	0	1	0	0	41
Soft tissue	10	4	2	5	4	2	0	7	5	9	3	3	6	8	3	2	1	0	74
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	0	0	4
Skin	0	0	0	2	1	2	1	0	2	4	3	1	1	2	5	2	1	2	29
Breast	0	0	0	0	0	0	1	0	2	2	1	1	1	2	0	1	0	0	11
Prostate	0	0	0	0	0	0	0	0	2	1	4	19	24	30	22	10	8	7	127
Testis	1	0	0	0	8	10	16	13	5	1	3	0	1	0	0	0	0	0	58
Penis	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	2
Bladder	0	0	2	0	0	2	1	3	4	7	5	16	7	17	8	12	4	3	91
Kidney and renal pelvis	5	0	1	0	0	4	4	5	12	13	10	14	21	10	9	3	1	0	112
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Other urinary	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	1	0	3
Eye	10	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	11
Brain, CNS	16	10	9	15	9	13	17	15	21	10	16	15	16	10	7	2	0	0	201
Thyroid	0	0	1	2	1	5	10	14	9	9	7	6	3	4	0	2	0	0	73
Other endocrine	5	0	2	0	2	1	7	7	3	1	6	4	6	2	3	0	0	0	49
Hodgkin's disease	0	4	8	16	11	4	3	15	8	3	1	4	6	2	1	0	0	0	86
Non-hodgkin's lymphoma	1	4	2	3	7	7	8	15	17	7	14	15	14	10	6	6	4	2	142
Unknown or ill-defined	4	2	0	0	0	2	0	0	0	0	1	0	1	0	0	0	0	0	10
TOTAL	79	43	50	70	67	77	97	130	161	153	149	204	239	210	133	84	56	26	2028

TABLE 6  
ANALYTIC FEMALE CASES SEEN AT KFSH&RC BY SITE AND AGE  
(2024)

Site Group	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	TOTAL
Oral cavity	0	0	0	0	0	1	2	1	3	2	6	3	4	4	4	2	1	0	33
Nasopharynx	0	0	0	0	2	0	3	2	1	4	3	9	3	0	1	1	0	0	29
Esophagus	0	0	0	0	0	0	2	2	2	2	4	2	2	1	1	1	1	2	22
Stomach	0	0	0	0	2	2	4	3	4	3	5	3	9	2	1	3	1	0	42
Small intestine	0	0	0	0	0	0	0	1	0	2	0	0	2	1	1	0	0	1	8
Colon & Rectum	0	0	0	1	3	6	10	8	17	21	24	35	21	11	13	9	6	4	189
Anus,anal canal,anorectum	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2
Liver	0	0	0	1	1	1	0	0	0	1	3	10	8	9	3	8	0	6	51
Gallbladder	0	0	0	0	0	0	1	1	1	0	3	2	2	6	1	2	0	0	19
Bile ducts	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	0	0	0	5
Pancreas	0	0	0	0	0	0	2	2	1	2	3	9	4	2	7	2	1	1	36
Peritoneum, Retroperitoneum	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	3
Other digestive	0	0	0	1	0	0	0	0	1	0	2	0	3	1	0	2	1	0	11
Nasal cavity,sinus,ear	0	0	0	1	1	0	0	0	1	0	0	0	0	1	0	0	0	0	4
Lung	1	0	0	0	0	0	0	5	6	5	3	4	7	6	1	4	0	1	43
Other respir & thoracic	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Leukemia	21	8	7	9	7	7	6	11	11	5	5	7	9	8	4	1	0	0	126
Myeloma	0	0	0	0	0	0	0	1	2	2	3	7	1	2	1	0	0	0	19
Bone	1	4	8	4	0	1	2	2	1	1	1	1	1	1	0	1	0	0	29
Soft tissue	4	3	2	2	6	6	3	7	5	8	4	10	7	2	4	2	1	0	76
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2
Skin	0	0	0	0	0	1	0	1	1	0	1	1	2	0	1	0	3	2	13
Breast	0	0	0	1	3	15	32	76	106	129	90	106	99	50	28	11	6	4	756
Uterus	0	0	0	0	0	3	7	23	27	18	24	38	64	57	29	8	8	10	316
Ovary	1	0	0	2	1	4	5	7	4	11	7	10	5	12	6	3	0	2	80
Vagina	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	1	4
Vulva	0	0	0	0	1	1	0	0	1	0	0	1	1	0	1	1	0	0	7
Other female genital	0	0	0	0	0	0	1	0	0	0	0	1	1	1	0	0	1	0	5
Bladder	0	0	0	0	0	0	1	1	1	0	0	2	0	1	1	2	3	2	14
Kidney and renal pelvis	6	4	1	0	1	2	4	6	3	3	3	6	8	2	2	3	1	0	55
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
Eye	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8
Brain, CNS	10	9	8	11	10	14	21	23	24	37	36	23	12	19	7	6	4	0	274
Thyroid	0	0	2	10	11	28	35	28	26	20	21	17	14	8	2	1	1	1	225
Other endocrine	4	1	0	1	1	2	4	5	6	4	4	2	3	2	1	0	0	0	40
Hodgkin's disease	0	1	5	6	5	5	9	7	2	0	1	0	1	1	0	0	0	0	43
Non-hodgkin's lymphoma	2	2	1	5	2	6	2	11	10	3	10	15	15	9	6	2	1	2	104
Unknown or ill-defined	3	0	0	0	0	0	1	1	1	0	0	4	1	0	0	1	2	0	14
TOTAL	63	32	34	55	57	105	157	236	268	283	267	332	313	221	128	77	42	39	2709

**TRENDS IN RELATIVE FREQUENCY OF CANCER AT KFSH&RC (CONT'D)**

The crude relative frequencies of primary cancer cases seen at KFSH&RC are slightly different from those of the USA. The most common tumors of the USA are (Breast, Lung/Bronchus, and Colon), while Breast, Colon & Rectum, and Thyroid, CNS cancers are more common at KFSH&RC. The following 2024 cases exhibit significant differences:

**TABLE 7**  
**COMPARATIVE DATA - KFSH&RC VS USA AND KSA**  
(% to TOTAL CANCER CASES)

SITE	KFSH&RC 2024 (Hospital Level)	KSA 2023 (National Level)	USA 2024 (National Level)
BREAST	16.5%	20.3%	15.7%
BRAIN, CNS	9.7%	3.1%*	1.3%
COLON, RECTUM	8.5%	13.1%	5.3%
THYROID	6.1%	9.2%	7.6%
LEUKEMIA	5.8%	4.2%	3.1%
NON-HODGKIN LYMPHOMA	5.2%	4.7%	4.0%
UTERUS	6.7%	3.4%	3.4%
KIDNEY	3.4%	2.8%	4.1%
SOFT TISSUE	3.2%	1.5%	0.7%
LUNG/BRONCHUS	3.1%	3.2%	11.7%

\* Saudi cancer registry only reports malignant Brain& CNS cases

**Breast** – In 2024, Breast cancer is the most frequently diagnosed malignancy at KFSH&RC, accounting for 16.5% of all cases, compared to 15.7% of all neoplasms reported in the U.S. The Kingdom of Saudi Arabia (KSA) reported that breast cancer accounted for 20.3% of cases in 2023. At KFSH&RC, the majority of cases occur in women under the age of 50, in contrast to the United States, where breast cancer predominantly affects women over the age of 50. Similar to Western countries, breast cancer ranks as the leading cancer among women at KFSH&RC.

**Colon & Rectum** - cancer accounts for 8.5% of all malignancies at KFSH&RC, compared to 5.3% in the U.S., reflecting a slightly lower frequency than KFSH&RC for the year 2024. In 2023, KSA reported a percentage of 13.1%, which is higher than both KFSH&RC and the U.S. rates.

**Thyroid** – Thyroid cancer for 2024 cases constitutes 6.1% of all malignancies at KFSH&RC, a markedly higher proportion compared to the U.S., where it accounts for only 7.6 % of all cancer cases. KSA had more than these numbers with a percentage of 9.2% in 2023. This notable difference highlights the higher prevalence of thyroid cancer within the KSA and KFSH&RC patient population relative to Western countries.

**Brain, CNS** – The incidence of brain and CNS cancers is significantly higher at KFSH&RC in 2024, representing 9.7% of all malignancies. In comparison, these cancers constitute only 1.3% of all cases in the U.S. In 2023, KSA reported a higher percentage than the U.S. but lower than KFSH&RC, with brain and CNS cancers accounting for 3.1% of all cases.

**Leukemia** - Leukemia represents 5.8% of all malignancies at KFSH&RC, compared to 3.1% in the U.S. for the year 2024. This high relative frequency is particularly notable, as leukemia is the most common cancer among pediatric patients at the facility. In the previous year, KSA reported a leukemia incidence rate of 4.2%.

**Uterus** - Primary malignant neoplasms of the uterus in 2024 represent 6.7% of all cancers at KFSH&RC, compared to 3.4% in the U.S., indicating a slightly higher prevalence at KFSH&RC. In 2023, KSA reported a percentage of 3.4%, which is lower than KFSH&RC's similar to the U.S. rate.

**Non-Hodgkin Lymphoma** - Non-Hodgkin Lymphoma (NHL) in 2024 constitutes 5.2% of all cancers at KFSH&RC, compared to 4.0% in the U.S., reflecting a higher relative frequency at KFSH&RC. In 2023, KSA reported an NHL percentage of 4.7%, slightly lower than KFSH&RC, but significantly higher than the U.S. rate.

**Kidney** – Kidney cancer constitutes 3.4% of all cases at KFSH&RC in 2024, compared to 4.1% in the U.S., indicating a slightly higher incidence rate at the U.S. In 2023, KSA reported a percentage of 2.8%, somewhat less than KFSH&RC and significantly less than the U.S. rate.


**Soft tissue** – Soft tissue cancers account for 3.2% of all malignancies at KFSH&RC in 2024, compared to 0.7% in the U.S., reflecting a higher relative frequency of these tumors at KFSH&RC. In 2023, KSA reported a percentage of 1.5%, which is lower than KFSH&RC but higher than the U.S. rate.

**Lung/Bronchus** – Lung/Bronchus cancers account for 3.1% of all malignancies at KFSH&RC in 2024, which is slightly lower than the 11.7% reported in the U.S. In 2023, KSA reported a percentage of 3.2%, which is lower than the U.S. and slightly higher than KFSH&RC.

**FIGURE 12**  
**DISTRIBUTION OF 20 MOST COMMON MALIGNANCIES**  
 2024 ANALYTIC CASES\* (TOTAL CASES = 4,737)

### MALE

BRAIN, CNS	201 (9.9%)
COLON & RECTUM	193 (9.5%)
LEUKEMIA	151 (7.4%)
NON-HODGKIN LYMPHOMA	142 (7%)
PROSTATE	127 (6.26%)
KIDNEY AND RENAL PELVIS	112 (5.5%)
LUNG & BRONCHUS	106 (5.2%)
LIVER	95 (4.7%)
BLADDER	91 (4.5%)
HODGKIN DISEASE	86 (4.2%)
SOFT TISSUE	74 (3.6%)
THYROID	73 (3.6%)
PANCREAS	73 (3.6%)
NASOPHARYNX	71 (3.5%)
TESTIS	58 (2.8%)
ORAL CAVITY	50 (2.47%)
OTHER ENDOCRINE	49 (2.42%)
STOMACH	43 (2.12%)
BONE	41 (2.02%)
SKIN CANCER	29 (1.43%)



### FEMALE

BREAST	756 (27.9%)
UTERUS	316 (11.6%)
BRAIN, CNS	274 (10.1%)
THYROID	225 (8.3%)
COLON & RECTUM	189 (6.9%)
LEUKEMIA	126 (4.6%)
NON-HODGKIN LYMPHOMA	104 (3.8%)
OVARY	80 (2.9%)
SOFT TISSUE	76 (2.8%)
KIDNEY & RENAL PELVIS	55 (2.03%)
LIVER	51 (1.8%)
HODGKIN LYMPHOMA	43 (1.6%)
LUNG/BRONCHUS	43 (1.6%)
STOMACH	42 (1.5%)
OTHER ENDOCRINE	40 (1.5%)
PANCREAS	36 (1.3%)
ORAL CAVITY	33 (1.2%)
BONE	29 (1.07%)
NASOPHARYNX	29 (1.07%)
ESOPHAGUS	22 (0.8%)


- This figure only categorizes analytic cases seen at KFSH&RC.
- Table 3 differentiates analytic and non-analytic cases.

**\*Analytic Cases definition:** An analytic case refers to a cancer patient who was diagnosed and/or received all or part of their first course of treatment at the facility reporting the data.


*As defined by the three main organizations, which maintain standard definitions in cancer registration:*

1. The Commission on Cancer (CoC): Part of the American College of Surgeons, published the Standards for Oncology Registry Entry (STORE).
2. The Surveillance, Epidemiology, and End Results (SEER) Program: managed by the National Cancer Institute (NCI),
3. North American Association of Central Cancer Registries (NAACCR).

**FIGURE 13**  
**DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES**  
 2024 ANALYTIC CASES\* (TOTAL CASES=288)



**FIGURE 14**  
**DISTRIBUTION OF 10 MOST COMMON PEDIATRIC MALIGNANCIES BY HISTOLOGY**  
 2024 ANALYTIC CASES\* (TOTAL CASES=288)



\*An analytic case refers to a cancer patient who was diagnosed and/or received all or part of their first course of treatment at the facility reporting the data.

**TABLE 8**  
**PRIMARY SITE (2024)**  
 (INCLUDES MULTIPLE PRIMARIES)

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		<b>5129</b>	<b>2016</b>	<b>2798</b>	<b>179</b>	<b>134</b>
<b>MOUTH &amp; OTHER ORAL CAVITY</b>		<b>33</b>	<b>16</b>	<b>17</b>	<b>0</b>	<b>0</b>
BASAL CELL CARCINOMA NODULAR		1	1	0	0	0
BASAL CELL CARCINOMA NOS		2	2	0	0	0
CARCINOMA NOS		1	1	0	0	0
CLEAR CELL ADENOCARCINOMA NOS		1	0	1	0	0
MUCOEPIDERMOID CARCINOMA		1	1	0	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		14	4	10	0	0
SQUAMOUS CELL CARCINOMA NOS		12	6	6	0	0
SQUAMOUS CELL CARCINOMA SPINDLE CELL		1	1	0	0	0
<b>GUM</b>		<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		2	2	0	0	0
<b>FLOOR OF MOUTH</b>		<b>3</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>
CARCINOMA NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA NOS		1	1	0	0	0
<b>TONGUE</b>		<b>33</b>	<b>20</b>	<b>13</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		1	1	0	0	0
MUCOEPIDERMOID CARCINOMA		2	2	0	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		13	10	3	0	0
SQUAMOUS CELL CARCINOMA NOS		17	7	10	0	0
<b>SALIVARY GLANDS</b>		<b>12</b>	<b>8</b>	<b>3</b>	<b>1</b>	<b>0</b>
ACINAR CELL CARCINOMA		1	0	1	0	0
ADENOCARCINOMA NOS		1	0	1	0	0
ADENOID CYSTIC CARCINOMA		4	3	1	0	0
BASAL CELL ADENOCARCINOMA		1	1	0	0	0
MALIGNANT MYOEPIHELIOOMA		2	2	0	0	0
MUCOEPIDERMOID CARCINOMA		3	2	0	1	0
<b>TONSIL</b>		<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>
SQUAMOUS CELL CARCINOMA, HPV-POSITIVE		1	1	0	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		1	1	0	0	0
<b>OROPHARYNX</b>		<b>4</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>0</b>
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		2	1	1	0	0
SQUAMOUS CELL CARCINOMA NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA, HPV-POSITIVE		1	1	0	0	0
<b>HYPOPHARYNX</b>		<b>8</b>	<b>3</b>	<b>5</b>	<b>0</b>	<b>0</b>
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		3	1	2	0	0
SQUAMOUS CELL CA LARGE CELL NONKERATINIZING NOS		1	0	1	0	0
SQUAMOUS CELL CARCINOMA NOS		4	2	2	0	0

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>NASOPHARYNX</b>		<b>92</b>	<b>67</b>	<b>24</b>	<b>1</b>	<b>0</b>
	ADENOCARCINOMA NOS	1	1	0	0	0
	CARCINOMA NOS	6	5	1	0	0
	CARCINOMA UNDIFFERENTIATED NOS	8	6	2	0	0
	SQUAMOUS CELL CARCINOMA KERATINIZING NOS	1	0	1	0	0
	SQUAMOUS CELL CA LARGE CELL NONKERATINIZING NOS	71	52	18	1	0
	SQUAMOUS CELL CARCINOMA NOS	5	3	2	0	0
<b>ESOPHAGUS</b>		<b>46</b>	<b>24</b>	<b>22</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	17	16	1	0	0
	GRANULAR CELL TUMOR MALIGNANT	1	1	0	0	0
	SQUAMOUS CELL CARCINOMA IN SITU NOS	1	0	1	0	0
	SQUAMOUS CELL CARCINOMA KERATINIZING NOS	4	1	3	0	0
	SQUAMOUS CELL CARCINOMA NOS	23	6	17	0	0
<b>STOMACH</b>		<b>90</b>	<b>46</b>	<b>44</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA INTESTINAL TYPE	13	8	5	0	0
	ADENOCARCINOMA NOS	47	27	20	0	0
	ATYPICAL CARCINOID TUMOR	4	1	3	0	0
	CARCINOID TUMOR NOS	2	2	0	0	0
	CARCINOMA DIFFUSE TYPE	2	1	1	0	0
	CARCINOMA NOS	1	0	1	0	0
	GASTROINTESTINAL STROMAL SARCOMA	10	4	6	0	0
	SIGNET RING CELL CARCINOMA	11	3	8	0	0
<b>SMALL INTESTINE</b>		<b>21</b>	<b>10</b>	<b>11</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	8	4	4	0	0
	ATYPICAL CARCINOID TUMOR	1	0	1	0	0
	CARCINOID TUMOR NOS	7	3	4	0	0
	GASTROINTESTINAL STROMAL SARCOMA	2	1	1	0	0
	MALIGNANT MELANOMA NOS	1	1	0	0	0
	NEUROENDOCRINE CARCINOMA NOS	2	1	1	0	0
<b>COLON</b>		<b>245</b>	<b>124</b>	<b>120</b>	<b>0</b>	<b>1</b>
	ADENOCARCINOMA NOS	224	110	114	0	0
	ATYPICAL CARCINOID TUMOR	1	0	1	0	0
	CARCINOID TUMOR NOS	6	4	1	0	1
	CARCINOMA IN SITU NOS	1	1	0	0	0
	CARCINOMA NOS	1	0	1	0	0
	MUCINOUS ADENOCARCINOMA	9	7	2	0	0
	MUCINOUS ADENOCARCINOMA IN SITU	1	1	0	0	0
	NEOPLASM IN SITU	1	1	0	0	0
	SIGNET RING CELL CARCINOMA	1	0	1	0	0
<b>RECTUM &amp; RECTOSIGMOID</b>		<b>190</b>	<b>99</b>	<b>91</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	183	94	89	0	0
	ATYPICAL CARCINOID TUMOR	1	1	0	0	0
	CARCINOID TUMOR NOS	4	3	1	0	0
	MUCINOUS ADENOCARCINOMA	1	1	0	0	0
	SIGNET RING CELL CARCINOMA	1	0	1	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>ANUS,ANAL CANAL,ANORECTUM</b>		<b>7</b>	<b>5</b>	<b>2</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		2	1	1	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA NOS		4	3	1	0	0
<b>LIVER</b>		<b>154</b>	<b>102</b>	<b>52</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		3	3	0	0	0
CHOLANGIOCARCINOMA		16	6	10	0	0
COMBINED HCC AND CHOLANGIOCARCINOMA		1	1	0	0	0
HEPATOCELLULAR CARCINOMA NOS		134	92	42	0	0
<b>GLALLBLADDER</b>		<b>26</b>	<b>6</b>	<b>20</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		25	6	19	0	0
ADENOSQUAMOUS CARCINOMA		1	0	1	0	0
<b>BILE DUCTS</b>		<b>27</b>	<b>21</b>	<b>6</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA INTESTINAL TYPE		2	2	0	0	0
ADENOCARCINOMA NOS		12	9	3	0	0
CHOLANGIOCARCINOMA		11	8	3	0	0
CHORIOCARCINOMA NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA NOS		1	1	0	0	0
<b>PANCREAS</b>		<b>125</b>	<b>84</b>	<b>41</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		99	67	32	0	0
ADENOSQUAMOUS CARCINOMA		1	1	0	0	0
ATYPICAL CARCINOID TUMOR		4	2	2	0	0
CARCINOID TUMOR NOS		10	6	4	0	0
CARCINOMA NOS		5	5	0	0	0
NEUROENDOCRINE CARCINOMA NOS		2	1	1	0	0
SMALL CELL CARCINOMA NOS		1	1	0	0	0
SOLID PSEUDOPAPILLARY CARCINOMA		3	1	2	0	0
<b>PERITONEUM &amp; RETROPERITONEUM</b>		<b>8</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>0</b>
ADENOCARCINOMA NOS		2	0	2	0	0
CARCINOSARCOMA NOS		1	0	1	0	0
MESOTHELIOMA MALIGNANT		1	1	0	0	0
MIXED GERM CELL TUMOR		1	1	0	0	0
NEUROBLASTOMA NOS		2	0	0	2	0
NEUROENDOCRINE CARCINOMA NOS		1	1	0	0	0
<b>OTHER DIGESTIVE</b>		<b>17</b>	<b>5</b>	<b>12</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		10	3	7	0	0
ATYPICAL CARCINOID TUMOR		1	0	1	0	0
GASTROINTESTINAL STROMAL SARCOMA		1	0	1	0	0
MUCINOUS ADENOCARCINOMA		1	1	0	0	0
NEUROENDOCRINE CARCINOMA NOS		2	1	1	0	0
SIGNET RING CELL CARCINOMA		2	0	2	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>NASAL CAVITY</b>		<b>12</b>	<b>8</b>	<b>4</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		1	0	1	0	0
ADENOID CYSTIC CARCINOMA		2	1	1	0	0
OLFACTORY NEUROBLASTOMA		1	0	1	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		2	2	0	0	0
SQUAMOUS CELL CARCINOMA NOS		6	5	1	0	0
<b>LARYNX</b>		<b>11</b>	<b>11</b>	<b>0</b>	<b>0</b>	<b>0</b>
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		5	5	0	0	0
SQUAMOUS CELL CARCINOMA NOS		5	5	0	0	0
SQUAMOUS CELL CARCINOMA SPINDLE CELL		1	1	0	0	0
<b>LUNG &amp; BRONCHUS</b>		<b>157</b>	<b>110</b>	<b>45</b>	<b>1</b>	<b>1</b>
ADENOCARCINOMA NOS		70	43	27	0	0
ADENOID CYSTIC CARCINOMA		2	0	2	0	0
ATYPICAL CARCINOID TUMOR		4	3	1	0	0
CARCINOID TUMOR NOS		5	2	3	0	0
CARCINOMA NOS		1	1	0	0	0
INVASIVE MUCINOUS ADENOCARCINOMA		1	1	0	0	0
MUCINOUS ADENOCARCINOMA		3	2	1	0	0
NEUROENDOCRINE CARCINOMA NOS		2	0	2	0	0
NON-SMALL CELL CARCINOMA		35	28	7	0	0
PLEOMORPHIC CARCINOMA		2	2	0	0	0
PLEUROPULMONARY BLASTOMA		2	0	0	1	1
PSEUDOSARCOMATOUS CARCINOMA		1	1	0	0	0
SPINDLE CELL CARCINOMA NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA KERATINIZING NOS		1	1	0	0	0
SQUAMOUS CELL CARCINOMA NOS		14	13	1	0	0
SMALL CELL CARCINOMA NOS		13	12	1	0	0
<b>PLEURA</b>		<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>
MESOTHELIOMA MALIGNANT		2	2	0	0	0
<b>OTHER RESPIR &amp; THORACIC</b>		<b>5</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>1</b>
GANGLIONEUROBLASTOMA		1	0	0	0	1
NEUROBLASTOMA NOS		3	0	0	3	0
SEMINOMA NOS		1	1	0	0	0
<b>MYELOMA</b>		<b>47</b>	<b>26</b>	<b>21</b>	<b>0</b>	<b>0</b>
MULTIPLE MYELOMA		45	25	20	0	0
PLASMACYTOMA NOS		2	1	1	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>BONE MARROW</b>		<b>298</b>	<b>114</b>	<b>93</b>	<b>53</b>	<b>38</b>
	ACUTE LEUKEMIA BURKITT TYPE	11	3	2	3	3
	ACUTE LEUKEMIA NOS	43	10	9	15	9
	ACUTE MEGAKARYOBLASTIC LEUKEMIA	1	0	0	1	0
	ACUTE MONOCYTIC LEUKEMIA	1	0	0	1	0
	ACUTE MYELOID LEUKEMIA M6 TYPE	4	1	2	1	0
	ACUTE MYELOID LEUKEMIA MINIMAL DIFFERENTIATION	1	1	0	0	0
	ACUTE MYELOID LEUKEMIA NOS	57	25	20	8	4
	ACUTE MYELOMONOCYTIC LEUKEMIA	1	0	0	0	1
	ACUTE PROMYELOCYTIC LEUKEMIA	2	1	0	0	1
	CHRONIC MYELOID LEUKEMIA NOS	27	15	12	0	0
	CHRONIC MYELOMONOCYTIC LEUKEMIA NOS	2	1	1	0	0
	ESSENTIAL THROMBOCYTHEMIA	7	1	2	1	3
	FOLLICULAR DENDRITIC CELL SARCOMA	2	2	0	0	0
	HAIRY CELL LEUKEMIA	5	5	0	0	0
	HYPEREOSINOPHILIC SYNDROME	1	0	0	0	1
	LANGERHANS CELL HISTIOCYTOSIS NOS	8	0	1	4	3
	LEUKEMIA NOS	38	14	2	12	10
	MYELODYSPLASTIC SYNDROME NOS	6	2	2	2	0
	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM	36	13	20	2	1
	MYELOID SARCOMA	3	2	1	0	0
	MYELOSCLEROSIS WITH MYELOID METAPLASIA	3	1	1	1	0
	PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA	1	0	0	1	0
	POLYCYTHEMIA VERA	1	0	1	0	0
	PROLYMPHOCYTIC LEUKEMIA T-CELL TYPE	1	0	1	0	0
	T-CELL LG GRAN LYMPH LEUK	6	2	1	1	2
	ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1	1	0	1	0	0
	ESSENTIAL THROMBOCYTHEMIA	8	6	2	0	0
	FOLLICULAR DENDRITIC CELL SARCOMA	1	0	1	0	0
	LANGERHANS CELL HISTIOCYTOSIS NOS	1	1	0	0	0
	MYELODYSPLASTIC SYNDROME NOS	14	5	9	0	0
	POLYCYTHEMIA VERA	5	3	2	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>SOFT TISSUE</b>		<b>163</b>	<b>65</b>	<b>73</b>	<b>16</b>	<b>9</b>
AMELOBLASTOMA MALIGNANT		1	1	0	0	0
CARCINOSARCOMA NOS		5	0	4	1	0
CHONDROSARCOMA NOS		2	2	0	0	0
DEDIFFERENTIATED LIPOSARCOMA		1	1	0	0	0
DERMATOFIBROSARCOMA NOS		11	4	7	0	0
DESMOPLASTIC SMALL ROUND CELL TUMOR		1	1	0	0	0
EMBRYONAL RHABDOMYOSARCOMA NOS		1	1	0	0	0
ENDOMETRIAL STROMAL SARCOMA NOS		4	0	4	0	0
EPITHELIOID HEMANGIOENDOTHELIOMA		1	0	1	0	0
EPITHELIOID SARCOMA		2	0	1	1	0
EWING SARCOMA		4	2	2	0	0
FIBROMYXOSARCOMA		1	0	1	0	0
FIBROSARCOMA NOS		1	1	0	0	0
GASTROINTESTINAL STROMAL SARCOMA		1	1	0	0	0
GIANT CELL SARCOMA (EXCEPT OF BONE)		4	3	1	0	0
HEMANGIOSARCOMA		5	4	1	0	0
INFANTILE FIBROSARCOMA		1	0	0	1	0
LEIOMYOSARCOMA NOS		19	3	16	0	0
LIPOSARCOMA NOS		10	4	6	0	0
LIPOSARCOMA WELL DIFFERENTIATED		3	2	1	0	0
MALIGNANT RHABDOID TUMOR		2	0	0	1	1
MALIGNANT PERIPHERAL NERVE SHEATH TUMOR		1	1	0	0	0
MYXOID CHONDROSARCOMA		1	1	0	0	0
MYXOID LIPOSARCOMA		4	3	1	0	0
NEOPLASM MALIGNANT		1	1	0	0	0
NEUROECTODERMAL TUMOR NOS		1	0	1	0	0
OSTEOSARCOMA NOS		2	1	0	1	0
PHYLLODES TUMOR MALIGNANT		1	0	1	0	0
PLEOMORPHIC LIPOSARCOMA		2	1	1	0	0
RHABDOMYOSARCOMA NOS		21	6	3	8	4
SARCOMA NOS		19	8	10	1	0
SOLITARY FIBROUS TUMOR MALIGNANT		1	1	0	0	0
SMALL CELL SARCOMA		1	0	0	1	0
SPINDLE CELL SARCOMA		18	8	8	1	1
STROMAL SARCOMA NOS		1	0	1	0	0
SYNOVIAL SARCOMA NOS		8	4	2	0	2
SYNOVIAL SARCOMA SPINDLE CELL		1	0	0	0	1

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>BONE</b>		<b>78</b>	<b>31</b>	<b>18</b>	<b>16</b>	<b>13</b>
	CHONDROBLASTIC OSTEOSARCOMA	1	1	0	0	0
	CHONDROID CHORDOMA	1	1	0	0	0
	CHONDROSARCOMA NOS	8	1	5	0	2
	CHORDOMA NOS	2	1	1	0	0
	EWING SARCOMA	24	6	3	8	7
	FIBROSARCOMA NOS	1	1	0	0	0
	GIANT CELL SARCOMA	1	0	1	0	0
	GIANT CELL TUMOR OF BONE MALIGNANT	5	3	2	0	0
	HEMANGIOSARCOMA	1	0	1	0	0
	LEIOMYOSARCOMA NOS	1	0	1	0	0
	NEUROECTODERMAL TUMOR NOS	1	1	0	0	0
	OSTEOSARCOMA IN PAGET DISEASE OF BONE	1	1	0	0	0
	OSTEOSARCOMA NOS	24	12	3	6	3
	SARCOMA NOS	1	1	0	0	0
	SPINDLE CELL SARCOMA	1	1	0	0	0
	CENTRAL OSTEOSARCOMA	1	0	0	1	0
	SMALL CELL SARCOMA	1	0	0	1	0
	TERATOMA MALIGNANT NOS (EXTRA-GONADAL)	1	0	0	0	1
	SQUAMOUS CELL CARCINOMA NOS	2	1	1	0	0
<b>SKIN (MELANOMA)</b>		<b>12</b>	<b>7</b>	<b>5</b>	<b>0</b>	<b>0</b>
	ACRAL LENTIGINOUS MELANOMA MALIGNANT	1	1	0	0	0
	MALIGNANT MELANOMA IN GIANT PIGMENTED NEVUS	1	1	0	0	0
	MALIGNANT MELANOMA NOS	8	4	4	0	0
	MELANOMA IN SITU	2	1	1	0	0
<b>SKIN (NON MELANOMA)</b>		<b>32</b>	<b>23</b>	<b>9</b>	<b>0</b>	<b>0</b>
	BASAL CELL CARCINOMA NODULAR	5	3	2	0	0
	BASAL CELL CARCINOMA NOS	13	8	5	0	0
	BASALOID SQUAMOUS CELL CARCINOMA	1	1	0	0	0
	DERMATOFIBROSARCOMA NOS	1	1	0	0	0
	PAPILLARY SYRINGADENOMA MALIGNANT	1	1	0	0	0
	SQUAMOUS CELL CARCINOMA IN SITU NOS	2	0	2	0	0
	SQUAMOUS CELL CARCINOMA NOS	9	9	0	0	0
<b>KAPOSIS SARCOMA</b>		<b>6</b>	<b>4</b>	<b>1</b>	<b>0</b>	<b>1</b>
	KAPOSI SARCOMA	6	4	1	0	1

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>BREAST</b>		<b>844</b>	<b>12</b>	<b>832</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	2	0	2	0	0
	CARCINOMA IN SITU NOS	1	0	1	0	0
	CARCINOMA NOS	10	0	10	0	0
	COMEDOCARCINOMA NONINFILTRATING	1	0	1	0	0
	CRIBRIFORM CARCINOMA IN SITU	1	0	1	0	0
	CRIBRIFORM CARCINOMA NOS	1	0	1	0	0
	INFILTRATING DUCT AND LOBULAR CARCINOMA	1	0	1	0	0
	INTRACYSTIC CARCINOMA NOS	1	0	1	0	0
	INTRADUCTAL CARCINOMA NONINFILTRATING NOS	63	0	63	0	0
	INVASIVE DUCTAL CARCINOMA	694	11	683	0	0
	INVASIVE MICROPAPILLARY CARCINOMA	2	0	2	0	0
	LOBULAR CARCINOMA IN SITU NOS	5	0	5	0	0
	LOBULAR CARCINOMA NOS	48	0	48	0	0
	METAPLASTIC CARCINOMA NOS	2	0	2	0	0
	MUCINOUS ADENOCARCINOMA	5	0	5	0	0
	NONINFILTRATING INTRACYSTIC CARCINOMA	1	1	0	0	0
	NONINFILTRATING INTRADUCT PAPILLARY ADENOC	1	0	1	0	0
	PAGET DISEASE AND INTRADUCTAL CARCINOMA IN SITU	1	0	1	0	0
	PAPILLARY CARCINOMA IN SITU	1	0	1	0	0
	PHYLLODES TUMOR MALIGNANT	1	0	1	0	0
	SECRETORY CARCINOMA OF BREAST	1	0	1	0	0
	TUBULAR ADENOCARCINOMA	1	0	1	0	0
<b>CERVIX UTERI</b>		<b>79</b>	<b>0</b>	<b>79</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA IN SITU, HPV-ASSOCIATED	1	0	1	0	0
	SQUAMOUS CARCINOMA SPINDLE IN SITU	1	0	1	0	0
	SQUAMOUS CELL CARCINOMA IN-SITU, HPV (+VE)	1	0	1	0	0
	SQUAMOUS INTRAEPITHELIAL NEOPLASIA GRADE III	9	0	9	0	0
	ADENOCARCINOMA NOS	10	0	10	0	0
	ADENOCARCINOMA, HPV-ASSOCIATED	1	0	1	0	0
	CARCINOMA NOS	3	0	3	0	0
	CARCINOSARCOMA NOS	1	0	1	0	0
	CLEAR CELL ADENOCARCINOMA NOS	1	0	1	0	0
	ENDOMETRIOID ADENOCARCINOMA NOS	1	0	1	0	0
	MESONEPHROMA MALIGNANT	1	0	1	0	0
	SEROUS CYSTADENOCARCINOMA NOS	3	0	3	0	0
	SQUAMOUS CELL CARCINOMA KERATINIZING NOS	1	0	1	0	0
	SQUAMOUS CELL CA LARGE CELL NONKERATINIZING NOS	5	0	5	0	0
	SQUAMOUS CELL CARCINOMA NOS	32	0	32	0	0
	SQUAMOUS CELL CARCINOMA, HPV-POSITIVE	8	0	8	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>CORPUS UTERI</b>		<b>256</b>	<b>0</b>	<b>256</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		26	0	26	0	0
ADENOSARCOMA		2	0	2	0	0
CARCINOMA NOS		2	0	2	0	0
CARCINOMA UNDIFFERENTIATED NOS		1	0	1	0	0
CARCINOSARCOMA NOS		15	0	15	0	0
CHORIOCARCINOMA NOS		1	0	1	0	0
CLEAR CELL ADENOCARCINOMA NOS		10	0	10	0	0
ENDOMETRIAL STROMAL SARCOMA NOS		2	0	2	0	0
ENDOMETRIOID ADENOCARCINOMA NOS		148	0	148	0	0
LEIOMYOSARCOMA NOS		1	0	1	0	0
MIXED CELL ADENOCARCINOMA		1	0	1	0	0
MUCINOUS ADENOCARCINOMA		1	0	1	0	0
SEROUS CYSTADENOCARCINOMA NOS		31	0	31	0	0
SQUAMOUS CELL CA LARGE CELL NONKERATINIZING NOS		2	0	2	0	0
SQUAMOUS CELL CARCINOMA NOS		8	0	8	0	0
SQUAMOUS INTRAEPITHELIAL NEOPLASIA GRADE III		4	0	4	0	0
TROPHOBLASTIC TUMOR EPITHELIOID		1	0	1	0	0
<b>UTERUS NOS</b>		<b>8</b>	<b>0</b>	<b>8</b>	<b>0</b>	<b>0</b>
ADENOCARCINOMA NOS		1	0	1	0	0
ADENOSARCOMA		1	0	1	0	0
SEROUS CYSTADENOCARCINOMA NOS		6	0	6	0	0
<b>OVARY</b>		<b>93</b>	<b>0</b>	<b>92</b>	<b>0</b>	<b>1</b>
ADENOCARCINOMA NOS		5	0	5	0	0
CLEAR CELL ADENOCARCINOMA NOS		2	0	2	0	0
DYSGERMINOMA		2	0	2	0	0
ENDOMETRIOID ADENOCARCINOMA NOS		3	0	3	0	0
GRANULOSA CELL TUMOR MALIGNANT		7	0	7	0	0
MICROPAPILLARY SEROUS CARCINOMA NON-INVASIVE		1	0	1	0	0
MUCINOUS ADENOCARCINOMA		7	0	7	0	0
MUCINOUS CYSTADENOCARCINOMA NOS		1	0	1	0	0
PARAGANGLIOMA MALIGNANT		1	0	1	0	0
SEROUS CYSTADENOCARCINOMA NOS		52	0	52	0	0
SEROUS SURFACE PAPILLARY CARCINOMA		5	0	5	0	0
SMALL CELL CARCINOMA NOS		1	0	1	0	0
STEROID CELL TUMOR MALIGNANT		1	0	1	0	0
TERATOMA MALIGNANT NOS		3	0	2	0	1
YOLK SAC TUMOR		2	0	2	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>VAGINA</b>		<b>4</b>	<b>0</b>	<b>4</b>	<b>0</b>	<b>0</b>
	CARCINOMA NOS	1	0	1	0	0
	SQUAMOUS CELL CARCINOMA NOS	2	0	2	0	0
	SQUAMOUS CELL CARCINOMA, HPV-POSITIVE	1	0	1	0	0
<b>VULVA</b>		<b>7</b>	<b>0</b>	<b>7</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	1	0	1	0	0
	BASAL CELL CARCINOMA NOS	1	0	1	0	0
	MALIGNANT MELANOMA NOS	1	0	1	0	0
	SQUAMOUS CELL CARCINOMA NOS	3	0	3	0	0
	SQUAMOUS CELL CARCINOMA, HPV-NEGATIVE	1	0	1	0	0
<b>OTHER FEMALE GENITAL</b>		<b>5</b>	<b>0</b>	<b>5</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	2	0	2	0	0
	CARCINOMA NOS	1	0	1	0	0
	CHORIOCARCINOMA NOS	1	0	1	0	0
	MUCINOUS ADENOCARCINOMA	1	0	1	0	0
<b>PROSTATE</b>		<b>151</b>	<b>151</b>	<b>0</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	151	151	0	0	0
<b>TESTIS</b>		<b>66</b>	<b>65</b>	<b>0</b>	<b>1</b>	<b>0</b>
	CHORIOCARCINOMA NOS	1	1	0	0	0
	EMBRYONAL CARCINOMA NOS	2	2	0	0	0
	GERMINOMA	2	2	0	0	0
	GRANULOSA CELL TUMOR MALIGNANT	1	1	0	0	0
	LEYDIG CELL TUMOR MALIGNANT	1	1	0	0	0
	MALIGNANT TERATOMA UNDIFFERENTIATED	1	1	0	0	0
	MIXED GERM CELL TUMOR	17	17	0	0	0
	SEMINOMA NOS	36	36	0	0	0
	SERTOLI-LEYDIG CELL TUMOR POORLY DIFFERENTIATED	1	1	0	0	0
	SPERMATOCYTIC SEMINOMA	1	1	0	0	0
	TERATOMA MALIGNANT NOS	1	1	0	0	0
	TERATOMA WITH MALIGNANT TRANSFORMATION	1	1	0	0	0
	YOLK SAC TUMOR	1	0	0	1	0
<b>PENIS</b>		<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>
	SQUAMOUS CELL CARCINOMA NOS	2	2	0	0	0
<b>BLADDER</b>		<b>116</b>	<b>99</b>	<b>15</b>	<b>2</b>	<b>0</b>
	ADENOCARCINOMA NOS	1	1	0	0	0
	CARCINOMA NOS	1	1	0	0	0
	EXTRA-ADRENAL PARAGANGLIOMA MALIGNANT	1	1	0	0	0
	PAPILLARY TRANSITIONAL CELL CARCINOMA	41	35	6	0	0
	PAPILLARY TRANSITIONAL CELL CA NON-INVASIVE	34	29	4	1	0
	SMALL CELL CARCINOMA NOS	1	1	0	0	0
	SQUAMOUS CELL CARCINOMA NOS	1	1	0	0	0
	TRANSITIONAL CELL CARCINOMA IN SITU	3	3	0	0	0
	TRANSITIONAL CELL CARCINOMA NOS	33	27	5	1	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>KIDNEY AND RENAL PELVIS</b>		<b>173</b>	<b>108</b>	<b>47</b>	<b>7</b>	<b>11</b>
	CARCINOMA NOS	2	2	0	0	0
	CLEAR CELL ADENOCARCINOMA NOS	15	13	2	0	0
	OXYPHILIC ADENOCARCINOMA	1	1	0	0	0
	PAPILLARY ADENOCARCINOMA NOS	8	6	2	0	0
	PAPILLARY TRANSITIONAL CELL CARCINOMA	1	1	0	0	0
	PAPILLARY TRANSITIONAL CELL CA NON-INVASIVE	1	0	1	0	0
	RENAL CELL CARCINOMA CHROMOPHOBE TYPE	19	13	6	0	0
	RENAL CELL CARCINOMA NOS	106	71	34	1	0
	SQUAMOUS CELL CARCINOMA NOS	1	0	1	0	0
	TRANSITIONAL CELL CARCINOMA NOS	2	1	1	0	0
	NEPHROBLASTOMA NOS	17	0	0	6	11
<b>URETER</b>		<b>2</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>
	PAPILLARY TRANSITIONAL CELL CA NON-INVASIVE	1	1	0	0	0
	TRANSITIONAL CELL CARCINOMA NOS	1	0	1	0	0
<b>OTHER URINARY</b>		<b>3</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>
	ADENOCARCINOMA NOS	1	1	0	0	0
	CLEAR CELL ADENOCARCINOMA NOS	1	1	0	0	0
	TRANSITIONAL CELL CARCINOMA NOS	1	1	0	0	0
<b>HODGKIN LYMPHOMA</b>		<b>136</b>	<b>77</b>	<b>43</b>	<b>12</b>	<b>4</b>
	HODGKIN LYMPHOMA LYMPHOCYTE DEPLETION NOS	1	0	1	0	0
	HODGKIN LYMPHOMA MIXED CELLULARITY NOS	13	7	2	3	1
	HL NODULAR LYMPHOCYTE PREDOMINANCE	12	8	3	0	1
	HODGKIN LYMPHOMA NODULAR SCLEROSIS NOS	38	19	15	3	1
	HODGKIN LYMPHOMA NOS	72	43	22	6	1
<b>NON- HODGKIN LYMPHOMA</b>		<b>267</b>	<b>142</b>	<b>109</b>	<b>9</b>	<b>7</b>
	ANAPLASTIC LARGE CELL LYMPHOMA T CELL & NULL CELL	5	1	4	0	0
	B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA, NOS	1	1	0	0	0
	B-CELL CLL/SMALL LYMPHOCYTIC LYMPHOMA	3	1	2	0	0
	BURKITT LYMPHOMA NOS	5	3	0	1	1
	CORTICAL T ALL	7	4	0	3	0
	FOLLICULAR LYMPHOMA GRADE 1	11	5	6	0	0
	FOLLICULAR LYMPHOMA GRADE 2	9	5	4	0	0
	FOLLICULAR LYMPHOMA GRADE 3	6	3	3	0	0
	FOLLICULAR LYMPHOMA NOS	9	5	4	0	0
	INTESTINAL T-CELL LYMPHOMA	1	1	0	0	0
	MALIGNANT LYMPHOMA LARGE B-CELL DIFFUSE NOS	95	50	42	0	3
	MALIGNANT LYMPHOMA NON-HODGKIN NOS	50	28	18	3	1
	MALIGNANT LYMPHOMA NOS	24	9	13	2	0
	MANTLE CELL LYMPHOMA	3	3	0	0	0
	MARGINAL ZONE B-CELL LYMPHOMA NOS	6	5	1	0	0
	MATURE T-CELL LYMPHOMA NOS	8	7	0	0	1
	MEDIASTINAL LARGE B-CELL LYMPHOMA	1	0	1	0	0
	MYCOSIS FUNGOIDES	19	9	9	0	1
	NK/T-CELL LYMPHOMA NASAL AND NASAL-TYPE	1	0	1	0	0
	PLASMABLASTIC LYMPHOMA	1	1	0	0	0
	PRIMARY FOLLICLE CENTRE LYMPHOMA	1	1	0	0	0
	T-CELL/HISTIOCYTE RICH LARGE B-CELL LYMPHOMA	1	0	1	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		<b>5129</b>	<b>2016</b>	<b>2798</b>	<b>179</b>	<b>134</b>
<b>EYE</b>		<b>20</b>	<b>1</b>	<b>1</b>	<b>10</b>	<b>8</b>
	ADENOCARCINOMA NOS	1	1	0	0	0
	RETINOBLASTOMA NOS	19	0	1	10	8
<b>THYROID</b>		<b>312</b>	<b>76</b>	<b>234</b>	<b>1</b>	<b>1</b>
	CARCINOMA ANAPLASTIC NOS	4	1	3	0	0
	CARCINOMA NOS	4	2	2	0	0
	FOLLICULAR ADENOCARCINOMA NOS	2	0	2	0	0
	FOLLICULAR CARCINOMA MINIMALLY INVASIVE	3	0	3	0	0
	ENCAPSULATED ANGOINVASIVE FTC	3	0	3	0	0
	INVASIVE ENCAPSULATED FOLLICULAR VARIANT PTC	4	0	4	0	0
	MEDULLARY CARCINOMA NOS	1	0	1	0	0
	MEDULLARY CARCINOMA WITH AMYLOID STROMA	2	0	2	0	0
	NON-INVASIVE FOLLICULAR THYROID NEOPLASM	2	0	2	0	0
	OXYPHILIC ADENOCARCINOMA	4	1	3	0	0
	PAPILLARY ADENOCARCINOMA NOS	268	68	199	1	0
	PAPILLARY CARCINOMA COLUMNAR CELL	10	1	9	0	0
	PAPILLARY CARCINOMA FOLLICULAR VARIANT	4	2	1	0	1
	PAPILLARY CARCINOMA OXYPHILIC CELL	1	1	0	0	0
<b>OTHER ENDOCRINE</b>		<b>95</b>	<b>46</b>	<b>36</b>	<b>7</b>	<b>6</b>
	ADENOCARCINOMA NOS	3	3	0	0	0
	ADENOMA NOS	27	11	6	6	4
	ADRENAL CORTICAL CARCINOMA	7	3	3	0	1
	ATYPICAL CARCINOID TUMOR	1	1	0	0	0
	CARCINOMA NOS	1	1	0	0	0
	CRANIOPHARYNGIOMA	2	1	1	0	0
	EXTRA-ADRENAL PARAGANGLIOMA MALIGNANT	1	1	0	0	0
	MUCOEPIDERMOID CARCINOMA	1	1	0	0	0
	NEUROBLASTOMA NOS	1	0	0	1	0
	PHEOCHROMOCYTOMA MALIGNANT	1	1	0	0	0
	PITUITARY CARCINOMA NOS	4	0	4	0	0
	PITUITARY ADENOMA NOS	37	19	17	0	1
	THYMIC CARCINOMA NOS	1	0	1	0	0
	THYMOMA TYPE AB MALIGNANT	1	1	0	0	0
	THYMOMA TYPE B2 MALIGNANT	3	2	1	0	0
	THYMOMA TYPE B3 MALIGNANT	4	1	3	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
<b>BRAIN,CNS</b>		<b>500</b>	<b>176</b>	<b>262</b>	<b>33</b>	<b>29</b>
ASTROBLASTOMA		1	1	0	0	0
ASTROCYTOMA ANAPLASTIC		4	2	1	0	1
ASTROCYTOMA NOS		32	22	8	0	2
ATYPICAL MENINGIOMA		4	2	2	0	0
CAVERNOUS HEMANGIOMA		3	2	1	0	0
CENTRAL NEUROCYTOMA		2	0	2	0	0
CHORDOMA NOS		4	2	2	0	0
CHOROID PLEXUS PAPILOMA NOS		1	1	0	0	0
CRANIOPHARYNGIOMA		6	1	2	1	2
CRANIOPHARYNGIOMA ADAMANTINOMATOUS		2	0	1	1	0
DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT		2	0	2	0	0
DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR		4	2	2	0	0
EPENDYMOMA BENIGN		1	1	0	0	0
EPENDYMOMA NOS		13	4	3	4	2
EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES		1	0	0	0	1
GANGLIOGLIOMA NOS		10	2	4	2	2
GANGLIONEUROBLASTOMA		1	0	1	0	0
GANGLIONEUROMA		1	1	0	0	0
GERMINOMA		3	1	2	0	0
GLIOBLASTOMA NOS		52	27	25	0	0
GLIOBLASTOMA, IDH-MUTANT		5	1	4	0	0
GLIOMA BENIGN		8	7	0	1	0
GLIOMA MALIGNANT		54	22	16	8	8
GLIOSARCOMA		2	0	2	0	0
GLOMUS TUMOR NOS		1	0	1	0	0
HEMANGIOBLASTOMA		1	0	1	0	0
HEMANGIOMA NOS		1	0	0	1	0
JUVENILE ASTROCYTOMA (NON-FORDS)		2	0	0	1	1
MALIGNANT RHABDOID TUMOR		2	0	0	2	0
MEDULLOBLASTOMA NOS		20	6	4	9	1
MENINGIOMA MALIGNANT		1	1	0	0	0
MENINGIOMA NOS		68	11	56	1	0
MENINGOTHELIAL MENINGIOMA		1	0	1	0	0
MYXOPAPILLARY EPENDYMOMA		4	3	1	0	0

Classification: Public - عام

Classification: Public - عام

SITE	HISTOLOGY (NOS - Not Otherwise Specified)	ALL CASES	ADULTS		PEADIATRICS	
			MALE	FEMALE	MALE	FEMALE
		5129	2016	2798	179	134
NEOPLASM BENIGN		1	1	0	0	0
NERVE SHEATH TUMOR, NOS		2	0	2	0	0
NEURILEMOMA NOS		40	19	21	0	0
NEUROBLASTOMA NOS		1	0	0	0	1
NEUROFIBROMA NOS		1	0	1	0	0
OLIGODENDROBLASTOMA		1	0	1	0	0
OLIGODENDROGLIOMA ANAPLASTIC		2	1	1	0	0
OLIGODENDROGLIOMA NOS		10	3	7	0	0
PARANGLIOMA BENIGN		1	1	0	0	0
PILOCYTIC ASTROCYTOMA		10	2	3	1	4
PILOMYXOID ASTROCYTOMA		2	0	0	0	2
PINEOBLASTOMA		1	1	0	0	0
PLEOMORPHIC XANTHOASTROCYTOMA		3	1	1	0	1
SUBEPENDYMOMA		1	0	1	0	0
TERATOMA MALIGNANT NOS		1	1	0	0	0
TRANSITIONAL MENINGIOMA		1	0	1	0	0
ANGIOMATOUS MENINGIOMA		1	1	0	0	0
ATYPICAL MENINGIOMA		2	0	2	0	0
MENINGIOMA NOS		97	21	76	0	0
MENINGOTHELIAL MENINGIOMA		1	1	0	0	0
MYXOPAPILLARY EPENDYMOMA		1	0	1	0	0
ANGIOCENTRIC GLIOMA		1	0	0	0	1
NEURILEMOMA NOS		1	1	0	0	0
CHOROID PLEXUS CARCINOMA		1	0	0	1	0
<b>UNKNOWN PRIMARY SITE</b>		<b>22</b>	<b>4</b>	<b>11</b>	<b>4</b>	<b>3</b>
ADENOCARCINOMA NOS		4	0	4	0	0
ATYPICAL CARCINOID TUMOR		1	0	1	0	0
CARCINOID TUMOR NOS		1	0	1	0	0
CARCINOMA NOS		1	0	1	0	0
CARCINOMA UNDIFFERENTIATED NOS		1	1	0	0	0
CHORIOCARCINOMA NOS		1	1	0	0	0
GANGLIONEUROBLASTOMA		1	0	1	0	0
MESOTHELIOMA BIPHASIC MALIGNANT		1	1	0	0	0
NEUROBLASTOMA NOS		6	0	0	4	2
SMALL CELL CARCINOMA NOS		1	1	0	0	0
SQUAMOUS CELL CA LARGE CELL NONKERATINIZING NOS		1	0	1	0	0
SQUAMOUS CELL CARCINOMA NOS		2	0	2	0	0
YOLK SAC TUMOR		1	0	0	0	1

Classification: Public - عام

Classification: Public - عام

**TABLE 9**  
**MULTIPLE PRIMARY SITE TABLE**  
**2024**

PRIMARY SITE 2024	HISTOLOGY (NOS - Not Otherwise Specified)	OTHER PRIMARIES (PREVIOUS OR CONCURRENT)	ALL CASES	MALE	FEMALE
			100	26	74
<b>BREAST</b>			<b>48</b>	<b>0</b>	<b>48</b>
	Invasive ductal carcinoma	Lt Breast - Invasive ductal carcinoma	11	0	11
	Invasive ductal carcinoma	Rt Breast - Invasive ductal carcinoma	2	0	2
	Invasive ductal carcinoma	Lt Breast - Ductal carcinoma in situ	4	0	4
	Invasive ductal carcinoma	Rt Breast - Ductal carcinoma in situ	6	0	6
	Invasive ductal carcinoma	Lt Breast - Lobular carcinoma	1	0	1
	Invasive ductal carcinoma	Rt Breast - Lobular carcinoma	2	0	2
	Invasive ductal carcinoma	Lt Breast - Mucinous Adenocarcinoma	1	0	1
	Invasive ductal carcinoma	Rt Breast - Lobular carcinoma in situ	1	0	1
	Invasive ductal carcinoma	Lt Breast - Lobular carcinoma in situ	1	0	1
	Lobular carcinoma	Rt Breast - Ductal carcinoma in situ	3	0	3
	Lobular carcinoma	Lt Breast - Lobular carcinoma	3	0	3
	Lobular carcinoma	Rt Breast - Lobular carcinoma	1	0	1
	Ductal carcinoma in situ	Colon - Adenocarcinoma	1	0	1
	Ductal carcinoma in situ	Lt Breast - Ductal carcinoma in situ	2	0	2
	Ductal carcinoma in situ	Rt Breast - Invasive ductal carcinoma	2	0	2
	Ductal carcinoma in situ	Rt Breast - Invasive ductal carcinoma	1	0	1
	Invasive ductal carcinoma	Rt Lung - Carcinoid tumor	1	0	1
	Invasive ductal carcinoma	Thyroid - Papillary adenocarcinoma	3	0	3
	Invasive ductal carcinoma	Thyroid - Follicular thyroid carcinoma	1	0	1
	Invasive ductal carcinoma	Skin - Squamous cell carcinoma in situ	1	0	1
<b>COLON</b>			<b>7</b>	<b>2</b>	<b>5</b>
	Adenocarcinoma	Rt Breast - Ductal carcinoma in situ	1	0	1
	Adenocarcinoma	Rt Breast - Invasive ductal carcinoma	1	0	1
	Adenocarcinoma	Rt Lung - Neuroendocrine carcinoma	1	0	1
	Adenocarcinoma	Corpus Uteri - Endometrioid adenocarcinoma	1	0	1
	Adenocarcinoma	Lt Ovary - Steroid cell tumor	1	0	1
	Adenocarcinoma	Lt Kidney - Renal cell carcinoma	1	1	0
	Adenocarcinoma	Colon - Adenocarcinoma	1	1	0
<b>RECTOSIGMOID JUNCTION</b>			<b>1</b>	<b>0</b>	<b>1</b>
	Adenocarcinoma	Rt Breast - Ductal carcinoma in situ	1	0	1
<b>RECTUM</b>			<b>2</b>	<b>0</b>	<b>2</b>
	Adenocarcinoma	Corpus Uteri - Adenocarcinoma	1	0	1
	Adenocarcinoma	Lt Breast - Invasive ductal carcinoma	1	0	1
<b>SMALL INTESTINE</b>			<b>3</b>	<b>2</b>	<b>1</b>
	Carcinoid tumor	Tongue - Mucoepidermoid carcinoma	1	1	0
	Carcinoid tumor	Pancreas - Carcinoid tumor	1	0	1
	Carcinoid tumor	Bone Marrow - Multiple Myeloma	1	1	0
<b>GI TRACT</b>			<b>1</b>	<b>1</b>	<b>0</b>
	Adenocarcinoma	Bone - Ewing sarcoma	1	1	0
<b>STOMACH</b>			<b>1</b>	<b>0</b>	<b>1</b>
	Adenocarcinoma	Gastric Antrum - Adenocarcinoma	1	0	1
<b>GALLBLADDER</b>			<b>1</b>	<b>0</b>	<b>1</b>
	Adenocarcinoma	Skin - Basal cell carcinoma	1	0	1
<b>PROSTATE</b>			<b>1</b>	<b>1</b>	<b>0</b>
	Adenocarcinoma	Rt Lung - Adenocarcinoma	1	1	0
<b>TESTIS</b>			<b>2</b>	<b>2</b>	<b>0</b>
	Seminoma	Rt Testis - Seminoma	2	2	0

Classification: Public - عام

Classification: Public - عام

PRIMARY SITE 2024	HISTOLOGY (NOS - Not Otherwise Specified)	OTHER PRIMARIES (PREVIOUS OR CONCURRENT)	ALL CASES	MALE	FEMALE
			100	26	74
<b>NASOPHARYNX</b>			1	1	0
Nasopharynx - Nonkeratinizing Ca	Thyroid - Papillary adenocarcinoma		1	1	0
<b>HYPOPHARYNX</b>			1	1	0
Squamous cell carcinoma	Appendix - Low grade mucinous neoplasms		1	1	0
<b>LARYNX</b>			1	1	0
Squamous cell carcinoma spindle cell	Prostate Gland - Adenocarcinoma		1	1	0
<b>MOUTH</b>			2	2	0
Basal cell carcinoma	Stomach - Carcinoid tumor		1	1	0
Squamous cell carcinoma	Colon - Carcinoma in situ		1	1	0
<b>THYROID</b>			6	3	3
Papillary adenocarcinoma	Thyroid - Medullary carcinoma		2	1	1
Papillary adenocarcinoma	Bilateral Lung - Adenocarcinoma		1	0	1
Papillary adenocarcinoma	Rectum - Adenocarcinoma		1	0	1
Papillary adenocarcinoma	Nasopharynx - Nonkeratinizing Ca		1	1	0
Papillary adenocarcinoma	Pancreas - Carcinoid tumor		1	1	0
<b>BONE MARROW</b>			3	2	1
Multiple Myeloma	Thyroid - Papillary adenocarcinoma		1	0	1
Multiple Myeloma	Prostate Gland - Adenocarcinoma		1	1	0
Leukemia	Lymph Node - Mature T-cell lymphoma		1	1	0
<b>LYMPH NODES</b>			3	1	2
Marginal zone B-cell lymphoma	Thyroid - Papillary adenocarcinoma		1	0	1
Diffuse large B-cell Lymphoma	Rt Kidney - Renal cell carcinoma		1	0	1
Non hodgkin lymphoma	Bone Marrow - Hairy cell leukemia		1	1	0
	Skin - Kaposi sarcoma				
<b>KIDNEY</b>			2	2	0
Renal cell carcinoma	Rt Lung - Mucinous adenocarcinoma		1	1	0
Clear cell adenocarcinoma	Bone Marrow - chronic myeloid leukemia		1	1	0
<b>LIVER</b>			1	1	0
Hepatocellular carcinoma	Prostate Gland - Adenocarcinoma		1	1	0
<b>CERVIX UTERI</b>			2	0	2
Squamous cell carcinoma	Brain - Meningioma		1	0	1
Endometrioid adenocarcinoma	Rt Breast - Invasive ductal carcinoma		1	0	1
<b>CORPUS UTERI</b>			3	0	3
Endometrioid adenocarcinoma	Bone Marrow - Multiple Myeloma		1	0	1
Endometrioid adenocarcinoma	Lt Breast - Lobular carcinoma in situ		1	0	1
Serous cystadenocarcinoma	Lt Breast - Invasive ductal carcinoma		1	0	1
<b>BLADDER</b>			2	2	0
Papillary transitional cell ca. non-inv.	Lt Kidney - Renal cell carcinoma		1	1	0
Transitional cell carcinoma	Prostate Gland - Adenocarcinoma		1	1	0
<b>OVARY</b>			3	0	3
Serous cystadenocarcinoma	Lt Ovary- Serous cystadenocarcinoma		2	0	2
Serous cystadenocarcinoma	Rt Breast - Invasive ductal carcinoma		1	0	1
<b>BRAIN,CNS</b>			2	1	1
Oligodendroglioma	Brain - Meningioma		1	1	0
Glioblastoma	Thyroid - Anaplastic thyroid carcinoma		1	0	1
<b>THYMUS</b>			1	1	0
Thymoma type B2 malignant	Prostate Gland - Adenocarcinoma		1	1	0

Classification: Public - عام

Classification: Public - عام

## V. STAGE OF DISEASE AT DIAGNOSIS

Stage in any malignant process may be defined as the particular step, phase, or extent in a tumor's development, which is one of the predictors for outcome and treatment selection assigned at the time of initial diagnosis. The microscopic appearance, extent, and biological behavior of a tumor, as well as host factors, play a part in prognosis and are therefore important in staging.

The SEER (Surveillance, Epidemiology and End Results) Summary Staging Guide was utilized for all stageable cases. This system summarizes the disease categories into four general staging groups (i.e., in situ, localized, regional, and distant). Stage categories are based on a combination of clinical observations and operative-pathological evaluation.

Summary Staging Definitions:

IN SITU: Intraepithelial, noninvasive, noninfiltrating

LOCALIZED: Within organ

- a. Invasive cancer confined to the organ of origin
- b. Intraluminal extension where specified

REGIONAL: Beyond the organ of origin

- a. By direct extension to adjacent organs/tissues
- b. To regional lymph nodes
- c. Both (a) and (b)

DISTANT: Direct extension or metastasis

- a. Direct continuity to organs other than above
- b. Discontinuous metastasis
- c. To distant lymph nodes

In addition to the SEER Summary Staging, the cases were also staged according to the American Joint Committee on Cancer (AJCC) TNM system. This scheme is based on the premise that cancers of similar histology or site of origin share similar patterns of growth and extension. This system is based on the assessment of three components:

T: Extent of the primary tumor

N: Absence or presence and extent of regional lymph node involvement


M: Absence or presence of distant metastasis

Cases of Major sites of 2024, i.e., Breast, Brain& CNS, Colon and Rectum are presented in Table 10 with their clinical group stages and yearly comparative figures from 2020 to 2024.

Classification: Public - عام

Classification: Public - عام

**FIGURE 15**  
**DISTRIBUTION OF CASES BY (SEER) STAGE AT DIAGNOSIS**  
**2024 (TOTAL CASES = 5,129)**



Classification: Public - عام

Classification: Public - عام

**TABLE 10**  
**AJCC TNM GROUP STAGE OF ANALYTIC CASES OF MAJOR SITES**  
 \*BY YEAR  
 (2020-2024)

BREAST						
STAGE	2020	2021	2022	2023	2024	TOTAL
0	33	26	57	54	75	245
1	125	196	234	207	261	1023
2	121	162	185	195	164	827
3	124	200	200	186	169	879
4	86	127	147	147	162	669
UNKNOWN	16	16	32	48	13	125
TOTAL	505	727	855	837	844	3768

COLON & RECTUM						
STAGE	2020	2021	2022	2023	2024	TOTAL
0	2	2	3	2	2	11
1	13	24	25	30	48	140
2	32	61	43	70	68	274
3	72	128	150	134	172	656
4	101	144	162	152	133	692
UNKNOWN	4	10	15	9	12	50
Total	224	369	398	397	435	1823

Classification: Public - عام

Classification: Public - عام

UTERUS						
STAGE	2020	2021	2022	2023	2024	TOTAL
0	11	12	4	13	9	49
1	93	93	123	104	154	567
2	19	21	15	27	29	111
3	18	31	29	44	56	178
4	44	40	59	68	82	293
UNK	6	6	9	3	13	37
TOTAL	191	203	239	259	343	1235

THYROID						
STAGE	2020	2021	2022	2023	2024	TOTAL
0	8	4	2	2	0	16
1	186	262	303	299	254	1304
2	11	32	25	57	32	157
3	0	4	5	9	2	20
4	10	17	22	11	18	78
UNK	5	5	5	10	6	31
TOTAL	220	324	362	388	312	1606

KIDNEY & RENAL PELVIS						
STAGE	2020	2021	2022	2023	2024	TOTAL
0	0	0	0	0	1	1
1	20	47	57	59	78	261
2	8	9	5	14	13	49
3	23	32	29	42	44	170
4	15	31	24	22	31	123
UNK	8	6	12	4	6	36
TOTAL	74	125	127	141	173	640

- Brain, CNS: include benign tumors 2<sup>nd</sup> top cancer site at KFSH&RC, but not staged according to TNM staging.
- LEUKEMIA: 6<sup>th</sup> top cancer site at KFSH&RC, but not staged according to TNM staging.
- NON-HODGKIN LYMPHOMA (NHL): 7<sup>th</sup> top cancer site at KFSH&RC, but not staged according to TNM staging.

Classification: Public - عام

Classification: Public - عام

**TABLE 11**  
**ADDITIONAL CASES ADDED FOR (2020 – 2023)\***

NEW CASES ADDED	YEAR 1ST SEEN				
	2020	2021	2022	2023	Total
	53	80	162	142	437

**\* NOTE:**

- The number of cases depends on The Year first seen at KFSH&RC.
- These cases were missed (not included) in the previous TR Annual Report 2023

Classification: Public - عام

## VI. CANCER SURVIVAL AT KFSH&RC, RIYADH

Five-year observed survival for selected cancer sites at KFSH&RC, Riyadh, among patients diagnosed in 2019 and followed for five years through 2024.

The observed survival rates represent the percentage of people alive 5 years after diagnosis, regardless of the cause of death, according to the stage at presentation.

The statistics presented in this Survival report focus on analytic cases, as defined by the Commission on Cancer (CoC) and The Surveillance, Epidemiology, and End Results (SEER) Program. A case is classified as analytic if the reporting facility provided the initial diagnosis and/or administered all or part of the patient's first course of treatment.

The analytic cases reflect the primary responsibility of our clinical teams in managing new cancer diagnoses. By focusing on this specific cohort, we can accurately assess treatment outcomes, long-term survival rates, and the effectiveness of our multidisciplinary care in alignment with national benchmarks provided by the [SEER Program](#).

Cases with multiple primaries and In-situ were excluded.

**Reference:** Book 7: *Statistics and Epidemiology for Cancer Registries* published by the National Cancer Institute (NCI).

**TABLE 12**  
**5-YEAR OBSERVED SURVIVAL RATES\*\* (%)**  
**BY STAGE AT DIAGNOSIS, KFSH&RC**  
**Cases Diagnosed in 2019**

Site	2024 at KFSH (Hospital Level)		
	Localized	Regional	Distant
Breast Cancer	94%	83%	41%
Colorectal Cancer	91%	70%	24%
Hodgkin Lymphoma	100%	95%	89%
Non-Hodgkin Lymphoma	90%	82%	56%
Nasopharynx	100%	43%	25%
Thyroid	100%	100%	44%
Liver, HCC	50%	33%	13%

Classification: Public - عام

Classification: Public - عام

<b>Lung</b> <ul style="list-style-type: none"> <li>Non-Small Cell Lung Cancer (NSCLC)</li> <li>Small Cell Lung Cancer (SCLC)</li> </ul>	53%	39%	13%
	100%	NA	0%
<b>Prostate</b>	100%	79%	29%
<b>Pancreas</b>	33%	22%	2.7%
<b>Bladder</b>	63%	36%	20%
<b>Kidney</b>	92%	75%	32%

**LEUKEMIA\*\*\***  
**5-YEAR OBSERVED SURVIVAL RATES\*\* (%)**

Site	2024 at KFSH (Hospital Level)
<b>AML</b>	71%
<b>CML</b>	85%

\*Observed survival does not take into account death from other causes, the likelihood of which varies by cancer type due to differences in age distribution, and should be interpreted with caution.

\*\*Observed survival shown is for cases diagnosed in 2019 and followed through 2024.


\*\*\*Leukemia: Hematologic malignancies staged differently than Solid Tumors, reported survival for Some sub-types not all types seen at KFSH.

Classification: Public - عام

Classification: Public - عام

**FIGURE 16**  
**5-YEAR OBSERVED SURVIVAL RATES (%)**  
**BY STAGE AT DIAGNOSIS, KFSH&RC**  
**2024**

## *Breast*




Classification: Public - عام

Classification: Public - عام

## Colorectal


### Overall survival



Classification: Public - عام

Classification: Public - عام


## *Hodgkin Lymphoma*



Classification: Public - عام

Classification: Public - عام


## Non-Hodgkin Lymphoma



Classification: Public - عام

Classification: Public - عام

## *Nasopharynx Cancer*




Classification: Public - عام

Classification: Public - عام

## Thyroid Cancer


### Overall survival



Classification: Public - عام

Classification: Public - عام

## *Liver, HCC (Hepatic Cellular Carcinoma)*




Classification: Public - عام

Classification: Public - عام

## Lung Cancer Non-Small Cell Lung Cancer (NSCLC)


Overall survival



Classification: Public - عام

Classification: Public - عام

## Small Cell Lung Cancer (SCLC)




Classification: Public - عام

Classification: Public - عام

## Prostate Cancer

### Overall survival




Classification: Public - عام

Classification: Public - عام

## *Pancreatic Cancer*


### Overall survival



Classification: Public - عام


Classification: Public - عام

## Bladder Cancer



Classification: Public - عام


Classification: Public - عام



Classification: Public - عام

Classification: Public - عام

LEUKEMIA



Classification: Public - عام

**VII. APPENDIX****REQUESTS FOR TUMOR REGISTRY DATA  
2024****Feb**

- Hepatocellular carcinoma (HCC) 2014-2024. Saleh Alqahtani, MD
- Bone Marrow Transplant patients after 2000. Ayman Saad, MD
- Metastatic Osteosarcoma 2018-2023. Jean Paul Atallah, MD
- Kaposi Sarcoma cases 2000-2022. Nasser Alrajhi, MD
- Multiple Myeloma, aged 45 and younger. Waleed Rasheed, MD
- Acute Myeloid Leukemia cases 2015-2023 FLT3 mutated with Sorafenib. Ayman Saad, MD

**March**

- Rhabdomyosarcoma and Ewing Sarcoma 2000-2023. Abdulaziz Alghamdi, MD
- Lung Cancer cases 1988-2002
- Acute Lymphoblastic Leukemia (HCT) Therapy. Ayman Saad, MD

**May**

- Colorectal Cancer Cases 2017-2023. Saleh Alqahtani, MD

**July**

- Cervical and Esophageal Cancer Cases 2012-2022. Nasser Alrajhi, MD
- Esophageal Cancer cases 2002-2011. Ahmed Alsomali, MD

**August**

- Breast Cancer cases Stage IV and HER2 -ve 2018-2022. Mashari Alzahrani, MD

**September**

- Thyroid Cancer cases 2002-2023. Ali Alzahrani, MD
- Bladder, Ureter, and Renal Pelvis Cancer cases with muscle invasion or Mets 2022. S.Bazarbashi, MD
- All data of Follicular Lymphoma cases. Abdullah Alamer, MD
- Breast Cancer cases 2015-2019. Nasser Elkum, MD
- T-Cell Lymphoma cases 2008-2023. Alfadel Alshaibani, MD

**October**

- Nasopharyngeal Carcinoma cases 2000-2022. Almahmoud, MD
- Breast Cancer cases 2019-2023. Monther, MD
- All ENT Cancer cases 1975-2022.

**December**

- Salivary Gland Cancer Cases Number 2013-2023.

Classification: Public - عام

Classification: Public - عام

## VIII. REFERENCES

- American Joint Committee on Cancer (AJCC) TNM 8<sup>TH</sup> EDITION ([www.cancerstaging.org](http://www.cancerstaging.org))
- ICD-O: International Classification of Diseases for Oncology. Used to code the histology, behavior, and grade of a tumor. Registries are currently using the third edition of the ICD-O, ICD-O-3.1 VERSION ([www.naaccr.org](http://www.naaccr.org))
- Summary stage 2018 SEER ([www.seer.cancer.gov](http://www.seer.cancer.gov))
- Grade Coding Instructions and Tables ([naaccr.org](http://naaccr.org))
- Site-Specific Data Items ([naaccr.org](http://naaccr.org))
- SEER Program Coding and Staging Manual
- Class Of Case ([www.seer.cancer.gov/seertools/glossary](http://www.seer.cancer.gov/seertools/glossary))
- Multiple Primary and Histology Coding Rules Manual
- Standards for Oncology Registry Entry (STORE) Manual, Solid Tumor Rules
- American Cancer Society (<https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html>)
- **Book 7: Statistics and Epidemiology for Cancer Registries** (NIH Publication No. 94-3766). U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.

Classification: Public - عام

Classification: Public - عام

## IX. GLOSSARY OF TERMS

**Accessioned:** Cases are entered into the Tumor Registry by the year in which they were first seen at KFSH&RC for each primary cancer.

**Age of Patient:** Recorded in completed years at the time of diagnosis, and age group used as per the international standard.

**Analytic Cases:** Cases that were first diagnosed and/or received all or part of their first course of treatment at KFSH&RC.

**Non-Analytic Cases:** Cases diagnosed elsewhere and received their entire first course of treatment elsewhere.

**Case:** A diagnosis or finished abstract. A patient who has more than one primary is reported as multiple cases.

**Crude Relative Frequency:** The proportion of a given cancer in relation to all cases in a clinical or pathological series.

**First Course of Treatment:** The initial tumor-directed treatment or series of treatments, usually initiated within four months after diagnosis.

**Stage of Disease:** The extent of the disease process is determined at the first course of treatment.

### SEER (Surveillance, Epidemiology and End Results) Summary Staging:

**In Situ:** Tumor meets all microscopic criteria for malignancy except invasion.

**Local:** Tumor is confined to the organ of origin.

**Regional:** Tumor has spread by direct extension to immediately adjacent organs and/or lymph nodes and appears to have spread no further.

**Distant:** Tumor has spread beyond immediately adjacent organs or tissues by direct extension and/or has either developed secondary or metastatic tumors, metastasized to distant lymph nodes, or has been determined to be systemic in origin.

**AJCC (American Joint Committee on Cancer) TNM Staging:** A classification scheme based on the premise that cancers of similar histology or site or origin share similar patterns of growth and extension.

### T+N+M = Stage

**T:** Extent of primary tumor

**N:** Extent of regional lymph node involvement

**M:** Distant Metastasis

**Clinical Stage:** Classification based on the evidence acquired before treatment. Such evidence arises from physical examination, imaging, endoscopy, biopsy, surgical exploration and other relevant findings.

**Pathologic Stage:** Classification based on the evidence acquired before treatment, supplemented or modified by the additional evidence acquired from surgery and from pathologic examination of the resected specimen.

Classification: Public - عام